CURRICULUM VITAE

Stefan N. Constantinescu

NAME: Stefan N. CONSTANTINESCU

POSITIONS:

2021	Professor of Cancer Signaling (Full Professorial status), Nuffield Department of Medicine, University of Oxford and Senior Group Leader, Ludwig Institute for Cancer Research Oxford (0.25 FTE, from 15/04/2021).
2015	Professor of Cell Biology (Professeur ordinaire, 2018), Molecular Biology and Physiology at the Université catholique de Louvain, Health Science Sector and Faculty of Medicine, Brussels, Belgium.
2015-	Director of Research (Honorary), Fonds National de la Recherche Scientifique (FRS-FNRS) Belgium.
2012-	Professor (Part-Time) and President of the Cell Signaling Pole, de Duve Institute, Université catholique de Louvain.
2011-	Tenured Professor and Senior Researcher *FRS-FNRS* at the Université catholique de Louvain, Brussels, Belgium.
2010-	Member (equivalent Full-Professor or Professeur ordinaire), Ludwig Institute for Cancer Research, Brussels Branch.
2008-	Permanent Chargé de cours (Part-time) at the Université catholique de Louvain, Brussels, Belgium.
2005-	Associate Member, Ludwig Institute for Cancer Research, Brussels, Belgium.
2003-	Tenured Investigator of the FNRS (Chercheur qualifié, Fonds National de la Recherche Scientifique).
2003-	(Part-time) Associate Professor at the Université catholique de Louvain, Brussels, Belgium.
2003	Member, Christian de Duve Institute of Cellular Pathology, Brussels, Belgium.
2000-	Associate Member, Christian de Duve Institute of Cellular Pathology, Brussels, Belgium.
2000-	Group Leader, Ludwig Institute for Cancer Research, Brussels Branch of Cancer Genetics, Brussels, Belgium.
1995-2000	Anna Fuller Fellow in Molecular Oncology (1995-1998) & Postdoctoral Fellow of the The Medical Foundation, Boston (1998-2000), Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, MA (with Prof. Harvey F. Lodish).
1992-1994	Postdoctoral Research Associate, Department of Pathology, University of Tennessee, Memphis College of Medicine (with Prof. Lawrence M. Pfeffer), Memphis, TN, U.S.A.
1990-1992	Junior Lecturer, Departments of Cell Biology and Virology, University of Medicine and Pharmacy, Bucharest, and Research Associate, "Stefan S. Nicolau" Institute of Virology, Bucharest, Romania.

PROFESSIONAL ADDRESS:

Signal Transduction & Molecular Hematology Laboratory
Ludwig Institute for Cancer Research
& de Duve Institute, Cell Signaling Pôle
74, Avenue Hippocrate, UCL 7459
B-1200 Bruxelles
Belgique
Tél. : 02/764.75.40
Fax : 02/764.65.66
E-mail : Stefan.Constantinescu@bru.licr.org

PRIVATE ADDRESS:

Avenue de Tervueren 199, Bte 8
B-1150 Brussels
Belgium
Phone: 0032 - 2/764 75 40
Mobile: 0032 - 478/990 981

DATE AND PLACE OF BIRTH: June 6, 1964, Bucharest, Romania
NATIONALITY: Belgian and Romanian
CIVIL STATUS: Married, three children

EDUCATION/TRAINING:

2002	Université catholique de Louvain, Brussels, Belgium – Equivalence, Doctor (PhD) in Biomedical Sciences.
1991	University of Medicine and Pharmacy, Carol Davilla Bucharest, Romania – Ph.D. in Virology.
1988	University of Medicine and Pharmacy, Carol Davilla Bucharest, Romania – M.D. in Medicine. (Equivalence MD Belgium INAMI No. 1.77609.95.00)

TEACHING TASKS:

2015-	Course coordinator for Cell Biology (Cell and Molecular Biology, Experimental and Medical), Faculty of Medicine, Université catholique de Louvain.
2014-	Intracellular signaling and tumor biology, Université catholique de Louvain (in collaboration with Profs. Frédéric Lemaigre, Olivier Feron, Pierre Sonveaux and Anabelle Decottignies).
2013-	Cell Biology, Faculty of Dental Medicine, Université catholique de Louvain, (in collaboration with Profs. Christophe Pierreux and Donatienne Tyteca).
2011-	Cell Biology, Faculty of Medicine, Université catholique de Louvain, in collaboration with Prof. Pierre Courtoy).
2003-	Molecular Biology of Hormonal Regulation at the Université catholique de Louvain, 30h together with Prof. Frédéric Lemaigre.
2002-	Molecular Medicine (15h) at Carol Davilla University of Medicine and Pharmacy, Bucharest.
1997-1999	Course for Advanced Undergraduates, Massachusetts Institute of Technology, Department of Biology, 1 semester (Supervisor, Prof. H. Robert Horvitz).
1996-1997	Teaching Assistant for the Course 'Proteins as Drugs and Biotechnology', Massachusetts Institute of Technology (Supervisor Prof. Harvey F. Lodish).

HONORS AND AWARDS:

2022-2023	President, Royal Academy of Medicine of Belgium, Brussels, (Belgium).
2021	Alexandre and Gaston Tytgat Prize for research in cancer, Belgium.
2021-2024	President of the Federation of European Academies of Medicine (FEAM)
2020-2021	Vice-President, Royal Academy of Medicine of Belgium, Brussels, (Belgium).
2019	Membre titulaire, Royal Academy of Medicine of Belgium, Brussels, (Belgium).
2017	Welbio Investigator, Advanced Grant
2017	Prize for 2011-2015 of the Belgian Government for basic medical sciences medical research (Prix quinquennal des sciences médicales fondamentales 2011-2015).
2017	Special Recognition Award, Experimental Therapeutic Centre & D3 & A*Star, Singapore.
2016	Honorary Member, Romanian Academy.
2014	Pierre Stryckmans Lecture of the Belgian Society of Hematology.
2013	Membre associé, Royal Academy of Medicine of Belgium, Brussels, (Belgium).
2013	College of Alumni of the Royal Academy of Medicine of Belgium, Brussels, (Belgium).
2012	Member, Academy of Medical Sciences of Romania, Bucharest (Romania).
2011	Prize André Matthys-Bove (Prix scientifique « Madame veuve André Matthys-Bove »), Belgium.
2009-	Corresponding Member, Academy of Medical Sciences of Romania, Bucharest (Romania).
2004	Corresponding Member, Académie Européenne des Sciences, Lettres et Beaux-Arts, Paris (France).

2003	Maggy and Robert de Hovre Award in Immunology (Fondation Maggy et Robert de Hovre, Brussels, Belgium).
1998	The Medical Foundation Fellowship, Boston (U.S.A.).
1995-1998	Anna Fuller Fellow in Molecular Oncology, award shared between the M.I.T. Center for Cancer Research and the Boyer Center of the Yale University (U.S.A.).
1991	Prize of the Romanian Academy.

PROFESSIONAL SOCIETIES:

2011-2014	Board of the Belgian Society of Cell and Developmental Biology.
2010	Member, European Hematology Association.
2002-	International Member, American Society of Hematology.
2001-	Member, American Association for the Advancement of Science (AAAS).
2000-2012	Member, Advisory Board, ASPERA Educational Foundation, Boston, MA (U.S.A.).

REVIEW COMMITTEES OF SCIENTIFIC JOURNALS:

2016	Editor-in-Chief, *Journal of Cellular and Molecular Medicine, a Wiley open-access journal.*
2011-	Board of Associated Editors, *Frontiers in Molecular and Structural Endocrinology*.
2006-2010	Section Editor for the Signal Transduction section, *Leukemia* (The Journal of Normal and Malignant Hemopoiesis).
2000-	Editorial Board Member, *Journal of Cellular and Molecular Medicine.*
2000-	Reviewer for *Nature, Nature Medicine, Molecular Cell, Molecular and Cell Biology, Blood, Leukemia, Oncogene, Journal of Biological Chemistry, Hematologica, PLosONE, Proc. Natl. Acad. Sci. USA, Science.*
2000-	Reviewer for Israel Science Foundation, the Kay Kendall Fund, UK, National Scientific Agencies of Austria, Netherlands, Romania, EU FP6 and 7, ERC junior and advanced grants, MRC-UK, LLRF.

SCIENTIFIC COMMITTEES:

2020-	Member, Scientific Jury, Fondation contre le cancer, Brussels, Belgium
2019-	Member, Board of Directors, Salus Sanguinis Foundation, Brussels, Belgium.
2017-2020	Vice-President, Federation of the European Academies of Medicine, Brussels, Belgium.
2014-	Board of the SWG (Scientific Working Group) Myeloproliferative Neoplasms, European Hematology Association (EHA).
2014	Science Policy Committee Member, Federation of the European Academies of Medicine.
2013-	Advisory Board Special Research Program (SFB) in Myeloproliferative Neoplasms, National Austrian Funds, FWV, Vienna, Austria.
2013-	Global Myelofibrosis & Polycythemia Vera Advisory Board, Novartis.
2013-	Chair, Advisory Board Personal Genetics, Bucharest, Romania.
2012-	Scientific Advisory Board Member for JAK inhibitors, Novartis.
2011	Member, Scientific Program Committee for EHA (European Hematology Association) Meeting 2012 (EHA 17), Amsterdam, the Netherlands.
2011-2012	Member of the National Romanian Council for University Titles and Diploma Certification, Commissions for Biology and Biochemistry (Board) and Medicine, Ministry of Education, Romania.
2010	Member, Scientific Program Committee for EHA (European Hematology Association) Meeting 2011 (EHA 16), London, UK.
2010-	Scientific Advisory Board Member, Dafra Pharma, Belgium.
2009	Ad-Hoc Scientific Advisory Board Member for Anagrelide, Shire, UK.
2009	Ad-Hoc Scientific Advisory Board for Epo, Amgen, U.S.
2008-	Jury Member, European Research Council (ERC) Advanced Grants (2008, 2010, 2012).

2007	Chair, Scientific Advisory Board, Stefan S. Nicolau Institute of Virology, Academy of Romania, Bucharest, Romania.
2003-	Expert Evaluator, European Commission FP6 and FP7.
2002	Member, Scientific Advisory Board, Institute of Bioinformatics (in collaboration with Dr. Akhilesh Pandey, Johns Hopkins University, Baltimore, MD), Bangalore, India.

OTHER ACTIVITIES:

2017-	Consultant in Hematology (consultant interne), Service of Hematology, Cliniques universitaires Saint-Luc, Brussels
2017-	Founder MyeloPro Diagnostics and Research GmbH, Vienna
2002-	Professor of Molecular Medicine, Faculty of Medicine, Carol Davilla University of Medicine and Pharmacy, Bucharest.
2000-2002	Founding consultant, Therascope AG, Heidelberg, Germany (later Allantos, US, now Amgen).

PUBLICATIONS

BIBLIOMETRICS: (Google Scholar)

- Hirsch index: 64
- Number of citations: 19,376
- i10 index : 145

PRIMARY RESEARCH ARTICLES:

1. Patrascu I.V., **Constantinescu S.N.** & Dublanchet A. HIV-1 infection in Romanian children. *Lancet.* **335**(8690): 672, 1990. (IF: n/a)

2. Cernescu C., **Constantinescu S.N.** & Patrascu I.V. Measles antibodies in HIV-1 infected children. *Rev. Roum. Virol.* **41**(2): 133-134, 1990. (IF: n/a)

3. **Constantinescu S.N.,** Cernescu C., Balta F., Maniu H. & Popescu L.M. (1990). The priming effect of human interferon is mediated by protein kinase C. *J. Interferon Res.* **10**(6): 589-597, 1990. (IF: 1,438)

4. **Constantinescu S.N.**, Cernescu C. & Popescu L.M. Effects of protein kinase C inhibitors on viral entry and infectivity. *FEBS Letters* **292**(1-2): 31-33, 1991. (IF: 3,479)

5. Wang C., **Constantinescu S.N.**, MacEwan D.J., Strulovici B., Decker L.V., Parker P.J. & Pfeffer L.M. Interferon-α induces PKC-ε gene expression and a 4.7 kb PKC-ε -related transcript. *Proc. Natl. Acad. Sci. U.S.A.* **90**(15): 6944-6948, 1993. (IF: 10,325)

6. **Constantinescu S.N.**, Croze E., Wang C., Murti A., Basu L., Mullersman J. & Pfeffer L.M. Role of the IFN-α/β receptor chain 1 in structure and transmembrane signaling of the IFN αβ receptor complex. *Proc. Natl. Acad. Sci. U.S.A.* **91**(20): 9602-9606, 1994. (IF: 10,667)

7. Colamonici O.R., Porterfield B., Domanski P., **Constantinescu S.N.** & Pfeffer L.M. Complementation of the interferon α response in resistant cells by expression of the cloned subunit of the interferon-α receptor: A central role of this subunit in IFN-α signaling. *J. Biol. Chem.* **269(13)**: 9698-9602, 1994. (IF: 7,716)

8. **Constantinescu S.N.**, Croze E., Murti A., Wang C., Basu L., Hollander D., Russell-Harde D., Betts M., Garcia-Martinez V., Mullersman J.E. & Pfeffer L.M. Expression and signaling specificity of the IFNAR chain of the type I IFN receptor complex. *Proc. Natl. Acad. Sci. U.S.A.* **92**(23): 10487-10491, 1995. (IF: 10,520)

9. Yang C.H., Shi W., Basu L., Murti A., **Constantinescu S.N.**, Blatt L., Croze E., Mullersman J.E. & Pfeffer L.M. Direct association of STAT3 with the IFNAR1 signal transducer chain of the type I IFN receptor. *J. Biol. Chem.* **271**(14): 8057-8061, 1996. (IF: 7,452)

10. Pfeffer L.M., Wang C., **Constantinescu S.N.,** Croze E., Blatt L.M., Albino A.P. & Nanus D.M. Human renal cancers resistant to IFN's antiproliferative action exhibit sensitivity to IFN's gene-inducing and antiviral actions. *J. Urol.* **156**(5): 1867-1871, 1996. (IF: 2,668)

11. Liu X., Sun Y., **Constantinescu S.N.**, Karam E., Weinberg R.A. & Lodish H.F. Transforming growth factor α-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. *Proc. Natl. Acad. Sci. U.S.A.* **94**(20): 10669-10674, 1997. (IF: 9,04)

12. Holland K.E., Owczarek C.M., Hwang S.Y., Tymms M.J., **Constantinescu S.N.**, Pfeffer L.M. & Hertzog P.J. A type I interferon signaling factor, ISF21, encoded on chromosome 21 is distinct from receptor components and their down-regulation and is necessary for transcriptional activation of IFN regulated genes. *J. Biol. Chem.* **272**(34): 21045-21051, 1997. (IF: 6,963)

13. Basu L., Yang C.H., Murti A., Garcia-Martinez V., Croze E., **Constantinescu S.N.**, Mullersman J.E. & Pfeffer L.M. The antiviral action of interferon is potentiated by removal of the conserved IRTAM domain of the IFNAR1 chain of the interferon α/β receptor: Effects on STAT activation and receptor down-regulation. *Virology* **242**(1): 14-21, 1998. (IF: 3,550)

14. **Constantinescu S.N.**, Wu H., Liu X., Beyer W., Fallon A. & Lodish H.F. The anemic Friend Virus gp55 envelope protein induces erythroid differentiation in fetal liver CFU-E's. *Blood* **91**(4): 1163-1172, 1998. (IF:8,3752)

15. **Constantinescu S.N.**, Liu X., Beyer W., Fallon A., Shekar S., Henis Y.I., Smith S.O. & Lodish H.F. Activation of the erythropoietin receptor by the gp55-P Viral envelope protein is determined by a single amino acid in its transmembrane domain. *EMBO J.* **18**(12): 3334-3347, 1999. (IF: 13,973)

16. Liu X., **Constantinescu S.N.**, Bogan J., Hirsch D. & Lodish H.F. Quantitative expression of genes at predetermined levels using bicistronic retroviral vectors. *Anal. Biochem.* **280**(1): 20-28, 2000. (IF:7,976)

17. **Constantinescu S.N.**, Huang L.J., Nam H & Lodish H.F. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. *Mol. Cell* **7**(2): 377-385, 2001. (IF: 16,611)

18. **Constantinescu S.N.**, Keren T., Socolovsky M., Nam H. & Lodish H.F. Ligand-independent oligomerization of the erythropoietin receptor is mediated by the transmembrane domain. *Proc. Natl. Acad. Sci. U.S.A.* **98**(8): 4379-4384, 2001. (IF: 10,896)

19. Huang L.J., **Constantinescu S.N.** & Lodish H.F. The N-terminal domain of Janus kinase 2 is required for cell-surface expression of erythropoietin and prolactin receptors. *Mol. Cell* **8**(6): 1327-1338, 2001. (IF: 16,611)

20. Pandey A., Ibarrola N., Kratchmarova I., Fernandez M.M., **Constantinescu S.N.**, Ohara O., Sawasdikosol S., Lodish H.F. & Mann M. A novel Src homology 2 domain-containing molecule, Src-like adapter protein-2 (SLAP-2), which negatively regulates T cell receptor signaling. *J. Biol. Chem.* **277**(21): 19131-19138, 2002. (IF: 6,696)

21. Lejeune D., Dumoutier L., **Constantinescu S.N.**, Kruijer W., Schuringa J.J. & Renauld J.C. IL-22 activates the JAK/STAT, ERK, JNK and p38 MAP kinase pathways in a rat hepatoma cell line: shared and distinct pathways from IL-10. *J. Biol. Chem.* **277(37)**: 33676-33682, 2002. (IF: 6,696)

22. Peri S., Navarro J.D., Amanchy R., Kristiansen T.Z., Jonnalagadda C.K., Surendranath V., Niranjan V., Muthusamy B., Gandhi T.K., Gronborg M., Ibarrola N., Deshpande N., Shanker K., Shivashankar H.N., Rashmi B.P., Ramya M.A., Zhao Z., Chandrika K.N., Padma N., Harsha H.C., Yatish A.J., Kavitha M.P., Menezes M., Choudhury D.R., Suresh S., Ghosh N., Saravana R., Chandran S., Krishna S., Joy M., Anand S.K., Madavan V., Joseph A., Wong G.W., Schiemann W.P., **Constantinescu S.N.**, Huang L., Khosravi-Far R., Steen H., Tewari M., Ghaffari S., Blobe G.C., Dang C.V., Garcia J.G., Pevsner J., Jensen O.N., Roepstorff P., Deshpande K.S., Chinnaiyan A.M., Hamosh A., Chakravarti A. & Pandey A. Development of human protein reference database as an initial platform for approaching systems biology in humans. *Genome Res.* **13**(10): 2363-2371, 2003. (IF: 9,635)

23. **Constantinescu S.N.**, Keren T., Russ W.P., Ubarretxena-Belandia I., Malka Y., Kubatzky K., Engelman D.M., Lodish H.F. & Henis Y.I. (2003) The Epo receptor transmembrane protein modulates complex formation with viral anemic and polycythemic gp55 proteins. *J. Biol. Chem.* **278**(44): 43755-43763, 2003. (IF: 6,482)

24. Seubert N., Royer Y., Staerk J., Kubatzky K.F., Moucadel V., Krishnqkumar S., Smith S.O. & **Constantinescu S.N.** Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. *Mol. Cell* **12**(5): 1239-1250, 2003. (IF: 16,835)

25. Royer Y., Menu C., Liu X. & **Constantinescu S.N.** High-throughput Gateway bicistronic retroviral vectors for stable expression in mammalian cells: exploring the biologic effects of STAT5 overexpression. *DNA Cell Biol.* **23**(6): 355-365, 2004. (IF: 2,398)

26. Kubatzky K.F., Liu W., Goldgraben K., Simmerling C., Smith S.O. & **Constantinescu S.N.** Structural requirements of the extracellular to transmembrane domain junction for erythropoietin receptor function. *J. Biol. Chem.* **280**(15): 14844-14854, 2005. (IF: 5,854)

27. Moucadel V. & **Constantinescu S.N.** Differential STAT5 signaling by ligand-dependent and constitutively active cytokine receptors. *J. Biol. Chem.* **280**(14): 13364-13373, 2005. (IF: 5,854)

28. Liu W., Crocker E. & **Constantinescu S.N.** Helix packing and orientation in the transmembrane dimer of gp55-P of the Spleen Focus Forming Virus. *Biophys. J.* **89**(2): 1194-1202, 2005. (IF: 4,507)

29. Sekkaï D., Gruel G., Herry M., Moucadel V., **Constantinescu S.N.**, Albagli O., Tronik-Le Roux D., Vainchenker W., Bennaceur-Griscelli A. Microarray analysis of LIF/Stat3 transcriptional targets in embryonic stem cells. *Stem Cells* **23**(10): 1634-42, 2005. (IF: 6,094)

30. Royer Y., Staerk J., Costuleanu M., Courtoy P.J. & **Constantinescu S.N.** Janus kinases affect thrombopoietin receptor cell surface localization and stability. *J. Biol. Chem.* **280**(29): 27251-27261, 2005. (IF: 5,854)

31. James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., **Constantinescu S.N.**, Casadevall N. & Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. *Nature* **434**(7037): 1144-1148, 2005. (IF: 29,273)

32. Staerk J., Kallin A., Demoulin J.B., Vainchenker W. & **Constantinescu S.N.** JAK1 and Tyk2 Activation by the homologous Polycythemia Vera JAK2 V617F mutation: Cross Talk with IGF1 Receptor *J. Biol. Chem.* **280**(51): 41893-41899, 2005. (IF: 5,854)

33. Sato T., Kienlen-Campard P., Ahmed M., Liu W., Li H., Elliott J.I., Aimoto S., **Constantinescu S.N.**, Octave J.N. & Smith S.O. Inhibitors of amyloid toxicity based on beta-sheet packing of Abeta40 and Abeta42. *Biochemistry* **45**(17): 5503-5516, 2006. (IF: 3,633)

34. Staerk J., Lacout C., Sato T., Smith S.O., Vainchenker W. & **Constantinescu S.N.** An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. *Blood* **107**(5): 1864-1871, 2006. (IF: 10,370)

35. Hookham M.B., Elliott J., Suessmuth Y., Staerk J., Ward A.C., Vainchenker W., Percy M.J., McMullin M.F., **Constantinescu S.N.** & Johnston J.A. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. *Blood* **109**(11): 4924-4929, 2007. (IF:10,896)

36. Knoops L., Hornakova T., Royer Y., **Constantinescu S.N.** & Renauld J.C. JAK kinases overexpression promotes in vitro cell transformation. *Oncogene* **27**(11): 1511-1519, 2008. (IF:7,216)

37. Wernig G., Gonneville J.R., Crowley B.J., Rodrigues M.S., Reddy M.M., Hudon H.E., Walz C., Reiter A., Podar K., Royer Y., **Constantinescu S.N.**, Tomasson M.H., Griffin J.D., Gary Gilliland D. & Sattler M. The Jak2V617F oncogene associated with myelopropliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. *Blood* **111**(7): 3751-3759, 2008. (IF: 10,432)

38. Dusa A., Staerk J., Elliott J., Pecquet C., Poirel H.A., Johnston J.A. & **Constantinescu S.N.** Substitution of JAK2 V617 by large non-polar amino acid residues causes activation of JAK2. *J. Biol. Chem.* **283**(19): 12941-12948, 2008. (IF: 5,520)

39. Lee Y., Hyung S.W., Jung H.J., Kim H.J., Staerk J., **Constantinescu S.N.**, Chang E.J., Lee Z.H., Lee S.W. & Kim H.H. The ubiquitin-mediated degradation of Jak1 modulates osteoclastogenesis by limiting interferon-induced inhibitory signaling. *Blood* **111**(2): 885-893, 2008. (IF:10,432)

40. Flex E., Petrangeli V., Stella L., Chiaretti S., Hornakova T., Knoops L., Ariola C., Fodale V., Clappier E., Paoloni F., Martinelli S., Fragale A., Sanchez M., Tavolaro S., Messina M., Cazzaniga G., Camera A., Pizzolo G., Tornesello A., Vignetti M., Battistini A., Cavé H., Gelb B.D., Renauld J.C., Biondi A., **Constantinescu S.N.**, Foà R. & Tartaglia M. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. *J. Exp. Med.* **205**(4): 751-758, 2008. (IF: 15,219)

41. Kienlen-Campard P., Tasiaux B., Van Hees J., Li M., Huysseune S., Sato T., Fei J.Z., Aimoto S., Courtoy P.J., Smith S.O., **Constantinescu S.N.*** & Octave J.N.* Amyloidogenic processing but not aicd production requires a precisely oriented APP dimer assembled by transmembrane GXXXG motifs. *J. Biol. Chem.* **283**(12): 7733-7744, 2008. (*Corresponding authors). (IF: 5,520)

42. Kumar K.G.S., Varghese B., Banerjee A., Baker D.P., **Constantinescu S.N.**, Pellegrini S. & Fuchs S.Y. Basal ubiquitin-independent internalization of interferon alpha receptor is prevented by Tyk2-mediated masking of a linear endocytic motif. *J. Biol. Chem.* **283**(27): 18566-18572, 2008. (IF: 5,520)

43. Gakovic M., Ragimbeau J., Francois V., **Constantinescu S.N.** & Pellegrini S. The Stat3-activating Tyk2 V678F mutant does not up-regulate signaling through the type I interferon receptor but confers ligand hypersensitivity to a homodimeric receptor. *J. Biol. Chem.* **283**(27): 18522-18529, 2008. (IF: 5,520)

44. Van Pelt K., Nollet F., Seileslag D., Knoops L., **Constantinescu S.N.**, Criel A. & Billiet J. The JAK2V617F mutation can occur in a hematopoietic stem cell that exhibits no proliferative advantage: a case of human allogeneic transplantation. *Blood* **112**(3): 921-922, 2008. (IF: 10,432)

45. Malinge S., Ragu C., Della-Valle V., Pisani D., **Constantinescu S.N.**, Perez C., Villeval J.L., Reinhardt D., Landman-Parker J., Michaux L., Dastugue N., Baruchel A., Vainchenker W., Bourquin J.P., Penard-Lacronique V. & Bernard O.A. Activating mutations in human acute megakaryoblastic leukemia. *Blood* **112**(10): 4220-6, 2008. (IF: 10,432)

46. Malka Y., Hornakova T., Royer Y., Knoops L., Renauld J.C., **Constantinescu S.N.*** & Henis Y.I. ***** Ligand-independent homomeric and heteromeric complexes between interleukin-2 or -9 receptor subunits and the gamma chain. *J. Biol. Chem.* **283**(48): 33569-33577, 2008. (*Corresponding authors) (IF: 5,520)

47. Hornakova T., Staerk J., Royer Y., Flex E., Tartaglia M., **Constantinescu S.N.**, Knoops L. & Renauld J.C. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers. *J. Biol. Chem.* **284**(11): 6773-6781, 2009. (IF: 5,328)

48. Sato T., Tang T.C., Reubins G., Fei J.Z., Fujimoto T., Kienlen-Campard P., **Constantinescu S.N.**, Octave J.N., Aimoto S. & Smith S.O. A helix-to-coil transition at the epsilon-cut site in the transmembrane dimer of the amyloid precursor protein is required for proteolysis. *Proc Natl Acad Sci U.S.A.* **106**(5): 1421-1426, 2009. (IF: 9,432)

49. Elliott J., Suessmuth Y., Scott L.M., Nahlik K., McMullin M.F., **Constantinescu S.N.**, Green A.R. & Johnston J.A. SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases. *Haematologica* **94**(4): 576-580, 2009. (IF: 6,416)

50. Marty C., Chaligné R., Lacout C., **Constantinescu S.N.**, Vainchenker W. & Villeval J.L. Ligand-independent thrombopoietin mutant receptor requires cell surface localization for endogenous activity. *J. Biol. Chem.* **284**(18): 11781-11791, 2009. (IF: 5,328)

51. Plo I., Zhang Y., Le Couédic J.P., Nakatake M., Boulet J.M., Itaya M., Smith S.O., Debili N., **Constantinescu S.N.**, Vainchenker W., Louache F. & de Botton S. An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. *J. Exp. Med.* **206**(8): 1701-1707, 2009. (IF: 14,505)

52. Pecquet C., Staerk J., Chaligné R., Goss V., Lee K.A., Zhang X., Rush J., Van Hees J., Poirel H.A., Scheiff J.M., Vainchenker W., Giraudier S., Polakiewicz R.D. & **Constantinescu S.N.** Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. *Blood* **115**(5): 1037-1048, 2010. (IF: 10,558)

53. Kandasamy K., Mohan S.S., Raju R., Keerthikumar S., Kumar G.S., Venugopal A.K., Telikicherla D., Navarro J.D., Mathivanan S., Pecquet C., Gollapudi S.K., Tattikota S.G., Mohan S., Padhukasahasram H., Subbannayya Y., Goel R., Jacob H.K., Zhong J., Sekhar R., Nanjappa V., Balakrishnan L., Subbaiah R., Ramachandra Y.L., Rahiman B.A., Prasad T.S., Lin J.X., Houtman J.C., Desiderio S., Renauld J.C., **Constantinescu S.N.**, Ohara O., Hirano T., Kubo M., Singh S., Khatri P., Draghici S., Bader G.D., Sander

C., Leonard W.J. & Pandey A. NetPath: a public resource of curated signal transduction pathways. *Genome Biol.* **11**(1): R3, 2010. (IF:6,885)

54. Girardot M., Pecquet C., Boukour S., Knoops L., Ferrant A., Vainchenker W., Giraudier S. & **Constantinescu S.N.** miR-28 Is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. *Blood* **116**(3): 437-445, 2010. (IF: 10,558)

55. Dusa A., Mouton C., Pecquet C., Herman M. & **Constantinescu S.N.** JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors. *Plos One* **5**(6): e11157, 2010. (IF: 4,411)

56. Besancenot R., Chaligné R., Tonetti C., Pasquier F., Marty C., Lécluse Y., Vainchenker W., **Constantinescu S.N.** & Giraudier S. Thrombopoietin induces senescence in mature megakaryocytes: implications for platet différentiation and malignant megakaryocyte prolifération. *Plos Biol.* **8**(9): e1000476, 2010. (IF: 12,469)

57. Medves S., Noel L.A., Montano-Almendras C.P., Albu R.I., Schoemans H., **Constantinescu S.N.** & Demoulin J.B. Multiple oligomerization domains of KANK1-PDGFRB are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK. *Haematologica* **96**(10): 1406-14, 2011. (IF: 6,424)

58. Hornakova T., Springuel L., Devreux J., Dusa A., **Constantinescu S.N.**, Knoops L. & Renauld J.C. Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors. *Haematologica* **96**(6): 845-53, 2011. (IF: 6,424)

59. Kleppe M., Soulier J., Asnafi V., Mentens N., Hornakova T., Knoops L., **Constantinescu S.N.**, Sigaux F., Meijerink J.P., Vandenberghe P., Tartaglia M., Foa R., Macintyre E., Haferlach T. & Cools J. PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. *Blood* **117(26)**: 7090-7098, 2011. (IF: 9,898)

60. Duhoux F.P., Ameye G., Lambert C., Herman M., Iossifidis S., **Constantinescu S.N.**, Libouton J.M, Demoulin J.B & Poirel H.A. New head-to-head gene fusion of MLL with ZC3H13 in a JAK2 V617F-positive patient with essential thrombocythemia without blast cells. *Leuk Res.* **36**(1): e27-30, 2011. (IF: 2,923)

61. Collard F., Vertommen D., **Constantinescu S.N.**, Buts L. & Van Schaftingen E. Molecular identification of beta-citrylglutamate hydrolase as glutamate carboxypeptidase 3. *J. Biol. Chem.* **286**(44): 38220-30, 2011. (IF: 4,773)

62. Albu R.I. & **Constantinescu S.N.** Extracellular domain N-glycosylation controls human thrombopoietin receptor cell surface levels. *Frontiers in Endocrinology* **2**(71): 1-12, 2011. (IF: n/a)

63. Staerk J., Defour J.P., Pecquet C., Leroy E., Poirel H.A., Brett I., Itaya M., Smith S.O., Vainchenker W. & **Constantinescu S.N.** Orientation-specific signalling by thrombopoietin receptor dimers. *EMBO J.,* **30**(21): 4398-4413, 2011. (IF: 9,205)

64. Ben Khalifa N., Tyteca D., Marinangeli C., Depuydt M., Collet J.F., Courtoy P.J., Renauld J.C., **Constantinescu S.N.**, Octave J.N. & Kienlen-Campard P. Structural features of the KPI domain control APP dimerization, trafficking and porcessing. *FASEB J.* **26**(2): 855-867, 2012. (IF:5,712)

65. Ben Khalifa N., Tyteca D., Courtoy P.J., Renauld J.C., **Constantinescu S.N.**, Octave J.N. & Kienlen-Campard P. Contribution of Kunitz protease inhibitor and transmembrane domains to amyloid precursor protein homodimerization. *Neurodegener Dis.* **10**(1-4): 92-5, 2012. (IF: 3,056)

66. Pecquet C., Diaconu C.C., Staerk J., Girardot M., Marty C., Royer Y., Defour J.P., Dusa A., Besancenot R., Giraudier S., Villeval J.L., Knoops L., Courtoy P.J., Vainchenker W. & **Constantinescu S.N.** Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. *Blood* 119(20): 4625-35, 2012. *(Introduced by Inside Blood comment by A. G. Fleischman and J. W. Tyner, Blood* **119***(20): 4579-4580).* (IF: 9,898)

67. Defour J.P., Itaya M., Gryshkova V., Brett I.C., Pecquet C., Sato T., Smith S.O. & **Constantinescu S.N.** A tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation. *Proc. Natl. Acad. Sci. USA* **110**(7): 2540-5, 2013. (IF: 9,809)

68. Mead A., Chowdhury O., Pecquet C., Dusa A., Woll P., Atkinson D., Burns A., Score J., Rugless M., Clifford R., Moule S., Bienz N., Vyas P., Cross N., Gale R.E., Henderson S., **Constantinescu S.N.**, Schuh A. & Jacobsen S. E. W. Impact of isolated germline JAK2 V617I mutation on human hematopoiesis. *Blood* **121**(20): 4156-65*,* 2013. (IF: 9,06)

69. Choong M.L., Pecquet C., Pendharkar V., Diaconu C.C., Yong J.W.Y., Tai S.J., Wang S.F., Defour J.P., Sangthongpitag K., Villeval J.L., Vainchenker W., **Constantinescu S.N.*** & Lee M.A.* Combination treatment for myeloproliferative neoplasms using JAK and pan class I PI3K inhibitors. *J Cell Mol Med.* **17**(11): 1397-409, 2013. (*Shared corresponding authorship) (IF: 4,753)

70. Cruceru M.L., Enciu A.M., Popa A.C., Albulescu R., Neagu M., Tanase C.P. & **Constantinescu S.N.** Signal transduction molecule patterns indicating potential glioblastoma therapy approaches. *Onco Targets Ther.* **6**: 1737-49, 2013. (IF: 2,85)

71. Mead A., Kharazi S., Atkinson D., Macaulay I., Pecquet C., Loughran S., Lutteropp M., Woll P., Chowdhury O., Luc S., Buza-Vidas N., Ferry H., Clark S.A., Goardon N., Vyas P., **Constantinescu S.N.**, Sitnicka E., Nerlov C., & Jacobsen S. E. W. FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors. *Cell Rep.* **3**(6): 1766-76*,* 2013. (IF:7,207)

72. Tang T.C., Hu Y., Kienlen-Campard P., El Haylani L., Decock M., Van Hees J., Fu Z., Octave J.N., **Constantinescu S.N.** & Smith S.O. Conformational changes induced by the A21G Flemish mutation in the amyloid precursor protein lead to increased Aβ production. *Structure* **22**(3): 387-96, 2014. (IF: 5,618)

73. Marty C., Saint Martin C., Pecquet C., Grosjean S., Saliba J., Mouton C., Leroy E., Harutyunyan A.S., Abgrall J.F., Favier R., Toussaint A., Solary E., Kralovics R., **Constantinescu S.N.,** Najman A., Vainchenker W., Plo I. & Bellanné-Chantelot C. Germline JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. *Blood* **123**(9): 1372-83, 2014. (IF: 10,452)

74. Woll P.S., Kjällquist U., Chowdhury O., Doolittle H., Wedge D.C., Thongjuea S. & al. (33 co-authors), **Constantinescu S.N.,** Nerlov C., Nilsson L., Campbell P.J., Sandberg R., Papaemmanuil E. Hellström-Lindberg E., Linnarsson S & Jacobsen S. E. W. Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo. *Cancer Cell* **25**(6): 794-808, 2014. (IF: 23,523)

75. Turnquist C., Wanga Y., Severs ona D.T., Zhonga S., Sunb B., Maa J., **Constantinescu S.N.**, Ansorged O., Stolpb H.B., Molnárb Z., Szeleb F.G. & Lu X. STAT1-induced ASPP2 transcription identifies a novel link between neuroinflammation, cell polarity, and tumor suppression. *Proc. Natl. Acad. Sci. USA* **111**(27): 9834-9, 2014. (IF: 9,674)

76. Besancenot R., Roos-Weil D., Tonetti C., Abdelouahab H., Lacout C., Pasquier F., Willekens, Rameau P.,

Lecluse Y., Micol J.B., **Constantinescu S.N.**, Vainchenker W., Solary E. & Giraudier S. JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferatin versus differentiation. *Blood* **124**(13): 2104-15, 2014. (IF: 10,452)

77. Cabagnols X., Defour J.P., Ugo V., Ianotto J.C., Mossuz P., Mondet J., Girodon F., Alexandre J.H, Mansier O., Viallard J.F, Lippert E., Murati A., Mozziconacci M.J., Saussoy P., Vekemans M.C., Knoops L., Pasquier F., Ribrag V., Solary E., Plo I., **Constantinescu S.N.**, Casadevall N., Vainchenker W., Marzac C. & Bluteau O. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocythemia: relevance for disease evolution. *Leukemia* **29**(1): 249-52 2015. (IF: 10,431)

78. Springuel L., Hornakova T., Losdyck E., Lambert F., Leroy E., **Constantinescu S.N.,** Flex E., Tartaglia M., Knoops L. & Renauld J.C. Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. *Blood* **124**(26): 3924-31*,* 2014. (IF: 10,452)

79. Shochat C., Tal N., Gryshkova V., Birger Y., Bandapall O.R., Cazzaniga G., Gershman N., Kulozik A.E., Biondi A., Mansour M.R., Twizere J.C., Muckenthaler M.U., Ben-Tal N., **Constantinescu S.N.,** Bercovich D. & Izraeli S. Novel activating mutations lacking cysteine in type I cytokine receptors in acute lymphoblastic leukemia. *Blood* **124**(1): 106-10, 2014. (IF: 10,452)

80. Marinangeli C., Tasiaux B., Opsomer R., Hage S., Sodero A.O., Dewachter I., Octave J.N., Smith S.O., **Constantinescu S.N.** & Kienlen-Campard P. Presenilin Transmembrane Domain 8 conserved AxxxAxxxG Motifs Are Required for the Activity of the γ-Secretase Complex. *J Biol Chem*. **290**(11): 7169-84, 2015. (IF: 4,258)

81. Girardot M., Pecquet C., Chachoua I., Van Hees J., Guibert S., Ferrant A., Knoops L., Beer P.A., Giraudier S., Moriggl R., Vainchenker W., Green A.R. & **Constantinescu S.N.** Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation. *Oncogene* **34**(10): 1323-32, 2015. (IF: 7,932)

82. Moraga I., Wernig G., Wilmes S., Gryshkova V., Richter C.P., Hong W.J., Sinha R., Guo F., Fabionar H., Wehrman T.S., Krutzik P., Demharter S., Plo I., Weissman I.L., Minary P., Majeti R., **Constantinescu S.N.**, Piehler J. & Garcia K.C. Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. *Cell* **160**(6): 1196-208, 2015. (IF: 28,710)

83. Arts F.A., Chand D., Pecquet C., Velghe A.I., **Constantinescu S.N.**, Hallberg B. & Demoulin J.B. PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib. *Oncogene* **35**(25): 3239-48, 2015. (IF: 7,932)

84. Losdyck E., Hornakova T., Springuel L., Degryse S., Gielen O., Cools J., **Constantinescu S.N.**, Flex E., Tartaglia M., Renauld J.C. & Knoops L. Distinct acute lymphoblastic leukemia (ALL)-associated Janus Kinase 3 (JAK3) mutants exhibit different cytokine-receptor requirements and JAK-inhibitor specificities. *J Biol Chem*. **290**(48): 29022-34, 2015. (IF: 4,258)

85. Decock M., El Haylani L., Stanga S., Dewachter I., Octave J.N., Smith S.O., **Constantinescu S.N.**, Kienlen-Campard P. Analysis by a highly sensitive split luciferase assay of the regions involved in APP dimerization and its impact on processing. *FEBS open bio*. **5**: 763-73, 2015. (IF: 2,101)

86. Martin-Lorenzo A., Hauer J., Vicente-Duenas C., Auer F., Gonzalez-Herrero I., Garcia-Ramirez I., Ginzel S., Thiele R., **Constantinescu S.N.**, Bartenhagen C., Dugas M., Gombert M., Schafer D., Blanco O., Mayado A., Orfao A., Alonso-Lopez D., De Las Rivas J., Cobaleda C., Garcia-Cenador M.B., Garcia-Criado F.J.,

Sanchez-Garcia I. & Borkhardt A. Infection exposure is a causal factor in B-precursor acute lymphoblastic leukemia as a result of Pax5 inherited susceptibility. *Cancer Discov.* **5**(12): 1328-43, 2015. (IF: 19,783)

87. Defour J.P., Chachoua I., Pecquet C. & **Constantinescu S.N.** Oncogenic activation of MPL/thrombopoietin receptor by 17 mutations at W515: implications for myeloproliferative neoplasms. *Leukemia* **30**(5):1214-6, 2016. (IF: 11,702)

88. Cabagnols X.*, Favale F.*, Pasquier F.*, Messaoudi K., Defour J.P., Ianotto J.C., Marzac C., Le Couédic J.P., Droin N., Chachoua I., Favier R., Diop M.K., Ugo V., Casadevall N., Debili N., Raslova H., Bellanne-Chantelot C., **Constantinescu S.N.**, Bluteau O., Plo I.§ & Vainchenker W.§ Presence of atypical thrombopoietin receptor (MPL) mutations in triple negative essential thrombocythemia patients. *Blood* **127**(3): 333-42, 2016. (*, §: These authors contributed equally) (IF: 13,164)

89. Milosevic Feenstra J.D., Nivarthi H., Gisslinger H., Leroy E., Rumi E., Chachoua I., Bagienski K., Kubesova B., Pietra D., Gisslinger B., Milanesi C., Jäger R., Chen D., Berg T., Schalling M., Schuster M., Bock C., **Constantinescu S.N.**, Cazzola M. & Kralovics R. Whole exome sequencing identifies novel MPL and JAK2 mutations in triple negative myeloproliferative neoplasms. *Blood* **127**(3): 325-32, 2016. (IF: 13,164)

90. Marty C., Pecquet C., Nivarthi H., Elkhoury M., Chachoua I., Tulliez M., Villeval J.L., Raslova H., Kralovics R., **Constantinescu S.N.**, Plo I. & Vainchenker W. Calreticulin mutants in mice induce MPL-dependent thrombocytosis with frequent progression to myelofibrosis. *Blood* **127**(10): 1317-24, 2016. (IF: 13,164)

91. Leroy E., Defour, J.P., Sato T., Dass S., Gryshkova V., Marlar S.M., Staerk J., **Constantinescu S.N.*** & Smith S.O.* His499 regulates dimerization and prevents oncogenic activation by asparagine mutations of the human thrombopoietin receptor. *J. Biol. Chem.* **291**(6): 2974-87, 2016. (*Shared corresponding authorship). (IF: 4,125)

92. Chachoua I., Pecquet C., El-Khoury M., Nivarthi H., Albu R.I., Marty C., Gryshkova V., Defour J.P., Vertenoeil G., Ngo A., Raslova H., Courtoy P.J., Choong M.L., Plo I., Vainchenker W., Kralovics R. & **Constantinescu S.N.** Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. *Blood* **127**(10): 1325-35, 2016. (IF: 13,164)

93. Balligand T., Achouri Y., Pecquet C., Chachoua I., Nivarthi H., Marty C., Vainchenker W., Plo I., Kralovics R. & **Constantinescu S.N.** Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin. *Leukemia* **30**(8): 1775-8, 2016. (IF: 11,702)

94. Leroy E., Dusa A., Colau D. Motamedi A., Cahu X., Mouton C., Huang L.J., Shiau A.K. & **Constantinescu S.N.** Uncoupling JAK2 V617F activation from cytokine-induced signaling by modulation of JH2 αC helix. *Biochem J.* **473**(11): 1579-1591, 2016. (IF: 3,797)

95. Decock M., Stanga S., Octave J.N., Dewachter I., Smith S.O., **Constantinescu S.N.*** & Kienlen-Campard P.* Glycines from the APP GXXXG/GXXXA Transmembrane Motifs Promote Formation of Pathogenic Abeta Oligomers in Cells. *Front Aging Neurosci.* **8**: 107, 2016. (*Corresponding authors). (IF: 4,504)

96. Nivarthi H., Chen D., Cleary C., Kubesova B., Jäger R., Bogner E., Marty C., Pecquet C., Vainchenker W., **Constantinescu S.N.** & Kralovics R. Thrombopoietin receptor is required for the oncogenic function of CALR mutants. *Leukemia* **30**(8): 1759-63, 2016. (IF: 11,702)

97. Kapralova K., Horvathova M., Pecquet C., Fialova Kucerova J., Pospisilova D., Leroy E., Kralova B., Milosevic Feenstra J.D., Schischlik F., Kralovics R., **Constantinescu S.N.** * & Divoky V. * Cooperation of germ line JAK2 mutations E846D and R1063H in hereditary erythrocytosis with megakaryocytic atypia. *Blood* **28**(10): 1418-23, 2016. (*Corresponding authors). (IF: 13,164)

98. Ngo A., Koay A., Pecquet C., Diaconu C.C., Ould-Amer Y., Huang Q., Kang C., Poulsen A., Lee M.A., Jenkins D., Shiau A., **Constantinescu S.N.** & Choong M.L. A phenotypic screen for small-molecule inhibitors of constitutively active mutant thrombopoietin receptor implicated in myeloproliferative neoplasms. *Comb. Chem. High Throughput Screen* **19**(10): 824-833, 2016. (IF 2015: 0,952)

99. Favale F., Messaoudi K., Varghese L.N., Boukour S., Pecquet C., Gryshkova V., Defour J.P., Albu R.I., Bluteau O., Ballerini P., Leverger G., Plo I., Debili N., Raslova H., Favier R., **Constantinescu S.N.*** & Vainchenker W.* An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L. *Blood* **128**(26): 3146-3158, 2016. (*Corresponding authors). (IF: 13,164)

100. Defour J.P., Hoade Y., Reuther A.M., Callaway A., Ward D., Chen F., **Constantinescu S.N.** & Cross N.C.P. An unusual, activating insertion/deletion MPL mutant in primary myelofibrosis. *Leukemia* **31**(8): 1838-1839, 2017. (IF: 10,023)

101. Degryse S., Bornschein S., de Bock C.E., Leroy E., Vanden Bempt M., Demeyer S., Jacobs K., Geerdens E., Gielen O., Soulier J., Harrison C.J., **Constantinescu S.N.** & Cools J. Mutant JAK3 signaling is increased by loss of wild type JAK3 or by acquiring secondary JAK3 mutations in T-ALL. *Blood* **131**(4): 421-425, 2017. (IF: 15,132)

102. Hu Y., Kienlen-Campard P., Tang T.C., Perrin F., Opsomer R., Decock M., Pan X., Octave J.N., **Constantinescu S.N.*** & Smith S.O.* β-sheet structure within the extracellular domain of C99 regulates amyloidogenic processing. *Sci Rep.* **7** (1): 17159, 2017. (*Corresponding authors). (IF: 4,122)

103. Pasquier F., Marty C., Balligand T., Verdier F., Grosjean S., Gryshkova V., Raslova H., **Constantinescu S.N.**, Casadevall N., Vainchenker W., Bellanné-Chantelot C. & Plo I. New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis. *Haematologica* **103**(4): 575-586, 2017. (IF: 9,090)

104. Barbieri D., Elvira-Matelot E., Pelinski Y., Genève L., de Laval B., Yogarajah G., Pecquet C., **Constantinescu S.N.** & Porteu F. Thrombopoietin protects hematopoietic stem cells from retrotransposon-mediated damage by promoting an antiviral response. *J. Exp. Med.* **215**(5): 1463-1480, 2018. (IF: 10,892)

105. Ngo A., Koay A., Pecquet C., Diaconu C.C., Jenkins D.A., Shiau A.K., **Constantinescu S.N.** & Choong M.L. Phenotypic screening for inhibitors of a mutant thrombopoietin receptor. *Methods Mol. Biol.* **1787**: 53-66, 2018. (IF: 10,710)

106. Mambet C., Babosova O., Defour J.P., Leroy E., Necula L., Stanca O., Tatic A., Berbec N., Coriu D., Belickova M., Kralova B., Lanikova L., Vesela J., Pecquet C., Saussoy P., Havelange V., Diaconu C.C., Divoky V. & **Constantinescu S.N.** Co-occurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in MPN patients. *Blood* **132**(25): 2695-2699, 2018. (IF: 16,562)

107. Defour J.P., Levy G., Leroy E., Smith S.O. & **Constantinescu S.N.** The S505A thrombopoietin receptor mutation in childhood hereditary thrombocytosis and essential thrombocythemia is S505N: single letter amino acid code matters. *Leukemia* **33**(2): 563-564, 2019. (IF: 8,665)

108. Leroy E., Balligand T., Pecquet C., Mouton C., Colau D., Shiau A.K., Dusa A. & **Constantinescu S.N.** Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling. *The Journal of Allergy and Clinical Immunology* **144**(1): 224-235, 2019. (IF: 10,228)

109. Tang T.C., Kienlen-Campard P., Hu Y., Perrin F., Opsomer R., Octave J.N., **Constantinescu S.N.** & Smith S.O. Influence of the familial Alzheimer's disease-associated T43I mutation on the transmembrane structure and γ-secretase processing of the C99 peptide. *J. Biol. Chem.* **294**(15): 5854-5866, 2019. (IF: 4,238)

110. Toppaldoddi K.R., da Costa Cacemiro M., Bluteau O., Panneau-Schmaltz B., Pioch A., Muller D., Villeval J.L., Raslova H., **Constantinescu S.N.**, Plo I., Vainchenker W. & Marty C. Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice. *Oncogene* **38**(10): 1651-1660, 2019. (IF 7,971)

111. Pecquet C., Chachoua I., Roy A, Balligand T., Vertenoeil G., Leroy E., Albu R.I., Defour J.P., Nivarthi H., Hug E., Xu E., Ould-Amer Y., Mouton C., Colau D., Vertommen D., Marlar S.M., Marty C., Plo I., Vainchenker W., Kralovics R. & **Constantinescu S.N.** Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants. *Blood* **133**(25): 2669-2681, 2019. (IF: 17,543)

112. Balligand T., Achouri Y., Pecquet C., Gaudray G., Colau D., Hug E., Rahmani Y., Stroobant V., Plo I., Vainchenker W., Kralovics R., Van den Eynde B., Defour J.P. & **Constantinescu S.N.** Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr Exon9 in cardiac development. *Leukemia*, **34**(2):510-521, 2020. (IF: 11,528)

113. Labuhn M., Perkins K., Papaemmanuil E., Matzk S., Varghese L., Metzner M., Kennedy A., Amstislavskiy V., Risch T., Bhayadia R., Samulowski D., Garnett C., Cruz Hernandez D., Stoilova B., Iotchkova V., Scheer C., Yoshida K., Schwarzer A., Taub J., Crispino J.D., Weiss M.J., Hayashi A., Taga T., Ito E., Ogawa S., Reinhardt D., Yaspo M.L., Campbell P.J., Roberts I., **Constantinescu S.N,** Vyas P., Heckl D. & Klusmann J.H. Mechanisms of progression of myeloid preleukemia to transformed myeloid leukemia in children with down syndrome. *Cancer Cell* **36**(2): 123-138, 2019. (IF: 26,602)

114. Milosevic T.V., Vertenoeil G., Payen V.L., Sonveaux P., Tulkens P.M., **Constantinescu S.N.** & Van Bambeke F. Prolonged inhibition and incomplete recovery of mitochondrial function in oxazolidinone-treated megakaryoblastic cell lines. *Int J Antimicrob Agents* **54**(5): 661-667, 2019. (IF: 4,621)

115. Patel A.B., Franzini A., Leroy E., Kim S.J., Pomicter A.D., Genet L., Xiao M., Yan D., Ahmann M., Agarwal A.M., Clair P., Addada J., Lambert J., Salmon M., Gleich G.J., Cross N.C.P., **Constantinescu S.N.**, O'Hare T., Prchal J.T. & Deininger M.W. JAK2ex13InDel drives oncogenic transformation and its association with chronic eosinophilic leukemia and polycythemia vera. *Blood* **134**(26): 2388-2398, 2019. (IF: 17,543)

116. Levy G., Carillo S., Papoular B., Cassinat B., Zini J.M., Leroy L., Varghese L., Chachoua I., Defour J.P., Smith S.O. & **Constantinescu S.N.** MPL Mutations in essential thrombocythemia uncover a common path of activation with eltrombopag dependent on W491. *Blood* **135**(12): 948-953, 2020. (IF: 22,113)

117. El-Khoury M., Cabagnols X., Mosca M., Vertenoeil G., Marzac C., Favale F., Bluteau O., Lorre F., Tisserand A., Rabadan Moraes G., Ugo V., Ianotto J.C., Rey J., Solary E., Roy L., Rameau P., Debili N., Pasquier F., Casadevall N., Marty C., **Constantinescu S.N.**, Raslova H., Vainchenker W. & Plo I. Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms. *Oncogene* **39**(31): 5323-5337, 2020. (IF: 9,867)

118. Benlabiod C., da Costa Cacemiro M., Nédélec A., Edmond V., Muller D., Rameau P., Touchard L., Gonin P., **Constantinescu S.N.**, Raslova H., Villeval J.L., Vainchenker W., Plo I. & Marty C. Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN. *Nat Commun.* **11**(1): 4886, 2020. (IF: 14,919)

119. Khourssaji M., Chapelle V., Evenepoel A., Belkhir L., Yombi J.C., van Dievoet M.A., Saussoy P., Coche E., Fillée C., **Constantinescu S.N.**, Rodriguez-Villalobos H., Defour J.P. & Gruson D. A biological profile for diagnosis and outcome of COVID-19 patients. *Clin Chem Lab Med.* **58**(12): 2141-2150, 2020. (IF: 3,694)

120. Jia R., Balligand T., Atamanyuk V., Nivarthi H., Xu E., Kutzner L., Weinzierl J., Nedelec A., Kubicek S., Lesyk R., Zagrijtschuk O., **Constantinescu S.N.** & Kralovics R. Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor. *Blood* **137**(14):1920-1931, 2020. (IF: 22,113)

121. Perrin F., Papadopoulos N., Suelves N., Opsomer R., Vadukul D.M. Vrancx C., Smith S.O. Vertommen D., Kienlen-Campard P. & **Constantinescu S.N.** Dimeric transmembrane orientations of APP/C99 regulate γ-secretase processing line impacting signaling and oligomerization. *iScience* 23(12): 101887, 2020 (IF: 5,458)

122. Carreño-Tarragona G., Varghese L., Sebastián E., Gálvez E., Marín-Sánchez A., López-Muñoz N., Nam-Cha S., Martínez-López J., **Constantinescu S.N. ***, Sevilla J. & Ayala R.*. A typical acute lymphoblastic leukemia JAK2 variant, R683G, causes an aggressive form of familial thrombocytosis when germline. *Leukemia* **35**: 3295-3298, 2021. (*Co-senior authors) (IF 2020: 11,528)

123. Basso-Valentino F., Levy G., Varghese L., Oufadem M., Neven B., Boussard C., Balayn N., Marty C., Vainchenker W., Plo I., Ballerini P., **Constantinescu S.N.**, Favier R. & Raslova H. CALR mutant protein rescues the response of MPL p.R464G variant associated with CAMT to eltrombopag. *Blood* **138**(6): 480-485, 2021. (IF 2020: 22,113)

124. Secardin L., Gomez Limia C., da Silva-Benedito S., Lordier L., El-Khoury M., Marty C., Ianotto J.C., Raslova H., **Constantinescu S.N.**, Bonamino M.H., Vainchenker W., Monte-Mor B., Di Stefano A. & Plo I. Induced pluripotent stem cells enable disease modeling and drug screening in Calreticulin del52 and ins5 myeloproliferative neoplasms. *Hemasphere* **5**(7): e593, 2021. (IF 2020: 1,56)

125. Mosca M., Hermange G., Tisserand A., Noble R.J., Marzac C., Marty C., Le Sueur C., Campario H., Vertenoeil G., El-Khoury M., Catelain C., Rameau P., Gella C., Lenglet J., Casadevall N., Favier R., Solary E., Cassinat B., Kiladjian J.J., **Constantinescu S.N.**, Pasquier F., Hochberg M.E., Raslova H., Villeval J.L., Girodon F., Vainchenker W., Cournède P.H. & Plo I. Inferring the dynamic of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms. *Blood* **138**(22): 2231-2243, 2021. (IF 2020: 22,113)

126. Varghese L., Carreño-Tarragona G., Levy G., Gutiérrez-López de Ocáriz X., Rapado I., Martínez-López J., Ayala R & **Constantinescu S.N.** MPL S505C enhances driver mutations at W515 in Essential Thrombocythemia. Blood Cancer Journal 11: 188, 2021. Doi: 10.1038/s41408-021-00583-4. (IF 2020: 11,037)

Selected References and Citations	Impact Factor	Number of Citations (2020)
Constantinescu S.N., Croze E., Wang C., Murti A., Basu L., Mullersman J. & Pfeffer L. M. Role of the IFN-α/β receptor chain 1 in structure and transmembrane signaling of the IFN αβ-receptor complex. *Proc. Natl. Acad. Sci. U.S.A.* **91**(20): 9602-9606, 1994.	10.667	**115**
Constantinescu S.N., Liu X., Beyer W., Fallon A., Shekar S., Henis Y.I., Smith S.O. & Lodish H.F. Activation of the erythropoietin receptor by the gp55-P Viral envelope protein is determined by a single amino acid in its transmembrane domain. *EMBO J.* **18**(12): 3334-3347, 1999.	13.973	**68**
Constantinescu S.N., Huang L.J., Nam H & Lodish H.F. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. *Mol. Cell* **7**(2): 377-385, 2001.	16.611	**180**
Constantinescu S.N., Keren T., Socolovsky M., Nam H. & Lodish H.F. Ligand-independent oligomerization of the erythropoietin receptor is mediated by the transmembrane domain. *Proc. Natl. Acad. Sci. U.S.A.* **98**(8): 4379-4384, 2001.	10.986	**301**
Huang L.J., **Constantinescu S.N.** & Lodish H.F. The N-terminal domain of Janus kinase 2 is required for cell-surface expression of erythropoietin and prolactin receptors. *Mol. Cell* **8**(6): 1327-1338, 2001.	16.611	**355**
Seubert N., Royer Y., Staerk J., Kubatzky K.F., Moucadel V., Krishnqkumar S., Smith S.O. & **Constantinescu S.N.** Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. *Mol. Cell* **12**(5): 1239-1250, 2003.	16.835	**200**
James C., Ugo V., Le Couedic J.P., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A., Villeval J.L., **Constantinescu S.N.**, Casadevall N. & Vainchenker W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. *Nature* **434**(7037): 1144-1148, 2005.	29.273	**3,649**
Staerk J., Kallin A., Demoulin J.B., Vainchenker W. & **Constantinescu S.N.** JAK1 and Tyk2 Activation by the homologous Polycythemia Vera JAK2 V617F mutation: Cross Talk with IGF1 Receptor *J. Biol. Chem.* **280**(51): 41893-41899, 2005.	5.854	**214**
Royer Y., Staerk, J., Costuleanu M., Courtoy P.J. & **Constantinescu S.N.** Janus kinases affect thrombopoietin receptor cell surface localization and stability. *J. Biol. Chem.* **280**(29): 27251-27261, 2005.	5,854	**175**
Staerk J., Lacout C., Sato T., Smith S.O., Vainchenker W. et **Constantinescu S.N.** An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. *Blood* **107**(5): 1864-1871, 2006.	10.370	**142**
Dusa A., Staerk J., Elliott J., Pecquet C., Poirel H.A., Johnston J.A. & **Constantinescu S.N.** Substitution of JAK2 V617 by large non-polar amino acid residues causes activation of JAK2. *J. Biol. Chem.* **283**(19): 12941-12948, 2008.	5520	**61**
Girardot M., Pecquet C., Boukour S., Knoops L., Ferrant A., Vainchenker W., Giraudier S. & **Constantinescu S.N.** miR-28 Is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. *Blood* **116**(3): 437-445, 2010.	10.558	**116**
Pecquet C., Staerk J., Chaligné R., Goss V., Lee K.A., Zhang X., Rush J., Van Hees J., Poirel H.A., Scheiff J.M., Vainchenker W., Giraudier S., Polakiewicz R.D. & **Constantinescu S.N.** Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. *Blood* **115**(5): 1037-1048, 2010.	10.558	**70**
Staerk J., Defour J.P., Pecquet C., Leroy E., Poirel H.A., Brett I., Itaya M., Smith S.S., Vainchenker W. & **Constantinescu S.N.** Orientation-specific signalling by thrombopoietin receptor dimers. *EMBO J.* **30**:4398-4413, 2011.	9.205	**55**
Pecquet C., Diaconu C.C., Staerk J., Girardot M., Marty C., Royer Y., Defour J.P., Dusa A., Besancenot R., Giraudier S., Villeval J.L., Knoops L., Courtoy P.J., Vainchenker W. &	9,898	**36**

Constantinescu S.N. Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. *Blood* 119(20): 4625-35, 2012.		
Defour J.P., Itaya M., Gryshkova V., Brett I.C., Pecquet C., Sato T., Smith S.O. & **Constantinescu S.N.** A tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation. *Proc. Natl. Acad. Sci. USA* **110**(7): 2540-5, 2013.	9,809	**54**
Girardot M., Pecquet C., Chachoua I., Van Hees J., Guibert S., Ferrant A., Knoops L., Beer P.A., Giraudier S., Moriggl R., Vainchenker W., Green A.R. & **Constantinescu S.N.** Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation. *Oncogene* **34**(10): 1323-32, 2015.	7,932	**13**
Moraga I., Wernig G., Wilmes S., Gryshkova V., Richter C.P., Hong W.J., Sinha R., Guo F., Fabionar H., Wehrman T.S., Krutzik P., Demharter S., Plo I., Weissman I.L., Minary P., Majeti R., **Constantinescu S.N.**, Piehler J. & Garcia K.C. Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. *Cell* **160**(6): 1196-208, 2015.	28,710	**84**
Chachoua I., Pecquet C., El-Khoury M., Nivarthi H., Albu R.I., Marty C., Gryshkova V., Defour J.P., Vertenoeil G., Ngo A., Raslova H., Courtoy P.J., Choong M.L., Plo I., Vainchenker W., Kralovics R. & **Constantinescu S.N.** Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. *Blood* **127**(10): 1325-35, 2016.	13,164	**191**
Favale F., Messaoudi K., Varghese L.N., Boukour S., Pecquet C., Gryshkova V., Defour J.P., Albu R.I., Bluteau O., Ballerini P., Leverger G., Plo I., Debili N., Raslova H., Favier R., **Constantinescu S.N.*** & Vainchenker W.* An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L. *Blood* **128**(26): 3146-3158, 2016. (*Corresponding authors).	13,164	**7**
Balligand T., Achouri Y., Pecquet C., Chachoua I., Nivarthi H., Marty C., Vainchenker W., Plo I., Kralovics R. & **Constantinescu S.N.** Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin. *Leukemia* **30**(8): 1775-8, 2016.	11,702	**48**

REVIEW ARTICLES:

1. Pfeffer L.M., **Constantinescu S.N.** & Wang C. Transmembrane signaling by IFN-α. *Prog. Mol. Subcell. Biol.* **14**: 242-259, 1994. (IF: n/a)

2. Watowich S.S., Wu H., Socolovsky M., Klingmuller U., **Constantinescu S.N.** & Lodish H.F. Cytokine receptor signal transduction and the control of hematopoietic cell development. *Annu. Rev. Cell Dev. Biol.* **12**: 91-129, 1996. (IF: 20,353)

3. **Constantinescu S.N.**, Ghaffari S. & Lodish H.F. The erythropoietin receptor: Structure, activation, and intracellular signal transduction. *Trends Endocrinol. Metab.* **10**(1): 18-23, 1999. (IF: 3,063)

4. **Constantinescu S.N.** Stem cell generation and choice of fate: role of cytokines and cellular microenvironment. *J. Cell. Mol. Med.* **4**(4): 233-248, 2000. (IF: n/a)

5. **Constantinescu S.N.** Stemness, fusion and renewal of hematopoietic and stem cells. *J. Cell. Mol. Med.* **7**: 103-112, 2003. (IF: n/a)

6. Vainchenker W. & **Constantinescu S.N.** A unique activating mutation in JAK2 is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. *Hematology (Am. Soc. Hematol. Educ. Program)* **195**: 195-200, 2005. (IF: 1,76)

7. Zhao Z.J., Krantz S.B., Vainchenker W., Casadevall N. & **Constantinescu S.N.** Role of tyrosine kinases and phosphatases in polycythemia vera. *Seminars in Hematology* **42**(4): 221-229, 2005. (IF: n/a)

8. James C., Ugo V., Casadevall N., **Constantinescu S.N.** & Vainchenker W. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. *Trends. Mol. Med.* **11**(12): 546-554, 2005. (IF: 5,505)

9. Delhommeau F., Pisani D.F., James C., Casadevall N., **Constantinescu S.N.** & Vainchenker W. Oncogenic mechanisms in myeloproliferative disorders. *Cell Mol. Life Sci.* **63**: 2939-2953, 2006. (IF: 4,655)

10. Staerk J., Kallin A., Royer Y., Diaconu C.C., Dusa A., Demoulin J.B., Vainchenker W., **Constantinescu S.N.** JAK2, the JAK2 V617F mutant and cytokine receptors. *Pathol Biol.* **55**(2): 88-91, 2007. (IF: 0,953)

11. Knoops L., Hermans C., Ferrant A. & **Constantinescu S.N.** Clinical implications of JAK2 mutations in myeloproliferative disorders. *Acta Belgica* **63**(2): 921-922, 2008. (IF: n/a)

12. Tefferi A. & **Constantinescu S.N.** Introduction to 'A special spotlight review series on BCR-ABL-negative myeloproliferative neoplasms'. *Leukemia* **22**(1): 1, 2008. (IF: 8,634)

13. Kota J., Caceres N. & **Constantinescu S.N.** Aberrant signal transduction pathways in myeloproliferative neoplasms. *Leukemia*. **22**(10): 1828-1840, 2008. (IF: 8,634)

14. Knoops L., Diaconu C.C. & **Constantinescu S.N.** The perspective of using JAK2 inhibitors in myeloproliferative neoplasms. Submitted as Invited Review in *Myeloproliferative Disorders in Practice*, Hayward Medical Communications, UK. **2**, 3-6, 2008. (IF: n/a)

15. **Constantinescu S.N.** Girardot M. & Pecquet C. Mining for JAK–STAT mutations in cancer. *Trends in Biochemical Sciences* **33**(3): 122-131, 2008. (IF: 11,572)

16. Vainchenker W., Dusa A. & **Constantinescu S.N.** JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. *Semin. Cell. Dev. Biol.* **19**(4): 385-393, 2008. (IF: 6,342)

17. **Constantinescu S.N.** Low platelet MPL and thrombocytosis: Levels matter. *Blood* **113**(8): 1617-1618, 2009. (IF: 10,555)

18. **Constantinescu S.N.** A new era for small molecule screening: from new targets, such as JAK2 V617F, to complex cellular screens. *J. Cell. Mol. Med.* **13**(2): 212-214, 2009. (IF: 5,228)

19. Khalifa N.B., Van Hees J., Tasiaux B., Huysseune S., Smith S.O., **Constantinescu S.N.**, Octave J.N. & Kienlen-Campard P. What is the role of amyloid precursor protein dimerization? *Cell Adh Migr.* **4**(2), 268-72, 2010. (IF: n/a)

20. Enciu A.M., **Constantinescu S.N.**, Popescu L.M., Mureşanu D.F. & Popescu B.O. Neurobiology of vascular dementia. *J Aging Res.* 2011: 401604, Epub Aug 17, 2011. (IF: n/a)

21. Vainchenker W., Delhommeau F., **Constantinescu S.N.** & Bernard O. New mutations and pathogenesis of myeloproliferative neoplasms. *Blood* **118**(7): 1723-35, 2011. (IF: 9,898)

22. Aapro M., Jelkmann W., **Constantinescu S.N.** & Leyland-Jones B. Effects of erythropoietin and erythropoiesis-stimulating agents on disease progression in cancer. *Br J Cancer* **106**(7): 1249-58, 2011. (IF: 5,042)

23. **Constantinescu S.N.** & Vainchenker W. Small molecule inhibitors in MPNs: are we aiming for the right targets? *Hematology Am. Soc. Hematol. Educ. Program*, 2012, 553-560, 2012. (IF: n/a)

24. Staerk J. & **Constantinescu S.N.** The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective. *JAK-STAT* 1:3, 184-190, 2012. (IF: n/a)

25. Vainchenker W. & **Constantinescu S.N.** JAK/STAT signaling in hematological malignancies. *Oncogene* **32**(21): 2601-13, 2013. (IF: 7,357)

26. **Constantinescu S.N.**, Leroy E., Gryshkova V., Pecquet C. & Dusa A. Activating Janus Kinase pseudokinase domain mutations in myeloproliferative and other blood cancers. *Biochem. Soc. Trans.* **41**(4): 1052-1058, 2013. (IF: 2,587)

27. Cruceru M.L., Neagu M., Demoulin J.B. & **Constantinescu S.N.** Therapy targets in glioblastoma and cancer stem cells: Lessons from haematopoietic neoplasms. *J Cell Mol Med.* **17**(10): 1218-35, 2013. (IF: 4,753)

28. Mead A.J., **Constantinescu S.N.** & Jacobsen S.E. Germline counterparts of oncogenic mutations: who gives a JAK? *Oncotarget* **4**(6): 814-5, 2013. (IF: 6,636)

29. **Constantinescu S.N.** Gathering support for critical mass: Interleukin 4 receptor signaling requires clustering in endosomes. *Biophys J.* 107(11): 2479-80, 2014. (IF: 3,972)

30. **Constantinescu S.N.** & Cahu X. Oncogenic drivers in myeloproliferative neoplasms: from JAK2 to calreticulin mutations. *Current Hematologic Malignancy Reports* **10**(4): 335-43, 2015. (IF: 2,146)

31. **Constantinescu S.N.** & Vainchenker W. JAK/STAT signalling and haematological malignancies. In *eLS*. John Wiley & Sons, Ltd : Chichester. doi:10.1002/9780470015902.a0024988, 2015. (IF: n/a)

32. Vainchenker W., **Constantinescu S.N.** & Plo I. Recent advances in understanding myelofibrosis and essential thrombocythemia. *F1000Res.* **5**: F1000 Faculty Rev-700, 2016. (IF: n/a)

33. Leroy E. & **Constantinescu S.N.** Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus Kinase inhibition. *Leukemia* **31**(5): 1023-1038, 2017. (IF: 10,023)

34. Varghese L.N., Defour J.P, Pecquet C. & **Constantinescu S.N.** The thrombopoietin receptor: Structural basis of traffic and activation by ligand, mutations, agonists, and mutated Calreticulin. *Front Endocrinol (Lausanne)* **8**: 59, 2017. (IF: 3,519)

35. Vainchenker W., Leroy E., Gilles L., Marty C., Plo I. & Constantinescu S.N. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. *F1000Res.* **7** F1000 Faculty Rev-82, 2018. (IF: n/a)

36. Wingelhofer B., Neubauer H.A., Valent P., Han X., **Constantinescu S.N.**, Gunning P.T., Müller M. & Moriggl R. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. *Leukemia* **32**(8): 1713-1726, 2018. (IF: 9,944)

37. Vainchenker W., Plo I., Marty C., Varghese L.N. & **Constantinescu S.N.** The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications. *Expert Review of Hematology* 12(6): 437-448, 2019. (IF: 2,573)

38. **Constantinescu S.N.** & Varghese L. MPL membrane domain sequencing goes deep. *Blood* **135**(4): 236-237, 2020. (IF: 22,113)

39. Abdeldayem A., Raouf Y.S., **Constantinescu S.N.**, Morrigl R. & Gunning P.T. Advances in covalent kinase inhinbitors. *Chem. Soc. Rev.* **49**(9): 2617-2687, 2020. *(IF: 54,564)*

40. Goyal, H., Chachoua, I., Pecquet, C., Vainchenker, W. & **Constantinescu, S.N.** A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia. *Blood Reviews* **42**: 100712, 2020. (IF: 8,250)

41. **Constantinescu, S.N.** & Pecquet, C. CALR mutations in MPN. (Educational Updates in Hematology Book), *HemaSphere* **4** (issue S2): 102-104, 2020. doi: 10.1097/HS9.0000000000000444. (IF: 1,56)
42. Valent P., Orfao A., Kubicek S., Staber P., Haferlach T., Deininger M., Kollmann K., Lion T., Virgolini I., Winter G., Hantschel O., Kenner L., Zuber J., Grebien F., Moriggl R., Hoermann G., Hermine O., Andreeff M., Bock C., Mughal T., **Constantinescu S.N.**, Kralovics R., Sexl V., Skoda R., Superti-Furga G. & Jäger U. Precision medicine in Hematology 2021: definitions, tools, perspectives, and open questions. *HemaSphere* **5** (3): e536. (IF: 1,56)

43. **Constantinescu S.N.**, Vainchenker W., Levy G. & Papadopoulos N. Functional consequences of mutations in myeloproliferative neoplasms. *HemaSphere* **5**(6) : e578, 2021. (IF: 1,56)

44. **Constantinescu S.N.** & Pecquet C. Degrading JAK2 in ALL by ruxolitinib-based PROTACs. *Blood* **138**(23): 2301-2302. (IF 2020: 22,113)

45. Levy G., Mambet C., Pecquet C., Bailly S., Havelange V., Diaconu C.C. & **Constantinescu S.N.** Targets in MPNs and potential therapeutics. *International Review of Cell and Molecular Biology* **366**: 41-81, 2022. (IF 2020: 6,813).

46. Levy G., Guglielmelli P., Langmuir P. & **Constantinescu S.N.** JAK inhibitors and COVID-19. *Journal for ImmunoTherapy of Cancer* **10**:e002838. doi:10.1136/ jitc-2021-002838, 2022.

BOOK CHAPTERS

1. Pfeffer L.M. & **Constantinescu S.N.** The molecular biology of IFN-beta from receptor binding to transmembrane signaling. *In*: Interferon Therapy in Multiple Sclerosis (Editor: A.T. Reder), Marcel Dekker Inc.: 1-41, 1996.

2. Socolovsky M., **Constantinescu S.N.**, Bergelson S., Sirotkin A. & Lodish H.F. Cytokines in hematopoiesis: specificity and redundancy in receptor function. In Cytokines (Editor: J. Wells), *Adv. Protein Chem.* (Editors F.M. Richards, D.S. Eisenberg and P.S. Kim), **52**: 141-198, 1998.

3. **Constantinescu S.N.** & Moucadel V. STAT signaling by erythropoietin. In *Signal Transducers and Activators of Transcription (STATs): Activation and Biology*, (Editors P. B. Sehgal, T. Hirano & D. E. Levy), Kluwer Academic Publishers, New York, 575-593, Dec. 2003.

4. Ghaffari S. & **Constantinescu S.N.** Erythropoietin and erythropoietin receptor: history, structure, interactions and intracellular signal transduction. *Encyclopedia of Molecular Medicine* (Editor, T. Creighton), John Wiley and Sons Inc. (Editor T. Creighton), doi 10.1002/0471203076.emm2011. 2004.

5. **Constantinescu S.N.** Mechanisms of Epo receptor activation. Book chapter In *Erythropoiesis and Erythropoietins* (Editors G. Molineux, M.A. Foote & S. Elliott), Birkhäuser Verlag AG, Basel, 175-196, 2009.

6. **Constantinescu S.N.** & Vainchenker W. New directions in MPN therapies: new targets. In Myeloproliferative Neoplasm Electronic Textbook - MPN eBook: A Clinicians Guide (Editors R. Mesa, C. Harrison, J.J. Kiladjian, A. Vannucchi and S. Verstovsek), Retrieved from http://g2npublishing.com/mpn/, 2014.

AUTHORSHIP AS MEMBER OF CONSORTIA

1. Bastard P. et al., **COVID Human Genetic Effort** & Casanova J.L. Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths. *Sci Immunol.* **6**(62):eabl4340, doi: 10.1126/sciimmunol.abl4340, 2021.

2. Asano T. et al., **COVID Human Genetic Effort** & Casanova J.L. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. *Sci Immunol.* **6**(62):eabl4348, doi: 10.1126/sciimmunol.abl4348, 2021.

3.Andreakos E. et al., **COVID Human Genetic Effort** & Spaan A.N. A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection. *Nat Immunol.* 1-6, doi: 10.1038/s41590-021-01030-z, 2021.

4. Zhang Q., Bastard P., **COVID Human Genetic Effort,** Cobat A. & Casanova J.L. Human genetic and immunological determinants of critical COVID-19 pneumonia. *Nature* doi: 10.1038/s41586-022-04447-0, 2022.

5. Brodin P., Casari G., Townsend L., O'Farrelly C., Tancevsky I., Löffler-Ragg J., Mogensen T.H., Casanova J.L. & **COVID Human Genetic Effort.** Studying severe long COVID to understand post-infectious disorders beyond COVID-19. Nat Med. doi: 10.1038/s41591-022-01766-7, 2022.

SELECTED SEMINARS, INVITED LECTURES

1. "Transmembrane signaling through the erythropoietin receptor", Imperial Cancer Research Fund (hosts: Prof. Richard M. Treisman and Prof. Sir Paul Nurse), February 2000, ICRF, Lincoln's Inn Fields, London.

2. "Mechanisms of signaling through the erythropoietin receptor, Stem Cells, Commitment and Carcinogenesis", Invited plenary lecture, Symposium of the DFGfunded SFB 465 "Development and Manipulation of Pluripotent Cells", Biozentrum Am Hubland, (Signal Transduction in Precursor and Stem Cells - Coordinator U.R. Rapp), October 12-14, 2000, Wuerzburg.

3. "Signaling through the erythropoietin receptor", Institute of Biochemistry (host: Prof. Heinrich Peter), January 2001, Aachen.

4. Constantinescu S.N., Huang L.J. & Lodish H.F. "The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented motif", Keystone Meeting, January 2001, Whistler.

5. "Role of the transmembrane and juxtamembrane domains of the erythropoietin receptor in signaling", Université Libre de Bruxelles, Graduate School of Informatics and Structural Biology (host: Prof. Shoshana Wodak), April 2001, Brussels.

6. "Cytokine receptor signaling", Université Libre de Bruxelles, Seminar series in Structure and function of membranes (host: Prof. J.M. Ruysschaert), June 2001, Brussels.

7. "Mechanisms of signaling through the erythropoietin receptor", Seminar series of the Institute of Interdisciplinary Research (IRIBHN), Université Libre de Bruxelles (host: Prof. Gilbert Vassart), September 2001, Brussels.

8. Huang L.J., Constantinescu S.N. & Lodish H.F. "The N-terminal domain of Janus Kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor", Keystone Meeting, January 2002, Snowbird, Utah.

9. Constantinescu S.N., Huang L.J. & Lodish H.F. How cytosolic membrane residues make the EpoR function: JAK2-dependent processing and signaling-EMBL/SALK Conference on Oncogenes and Growth Control, EMBL, p78, April 2002, Heidelberg.

10. "Role of transmembrane and juxtamembrane domains in signaling by cytokine receptors", Flanders Interuniversity Institute of Biochemistry, Ghent University, Department of Protein Chemistry (host: Prof. Jan Tavernier), April 2002, Ghent.

11. "Transmembrane signaling by the erythropoietin receptor", Plenary Guest Speaker, IIIrd International Aachen-Workshop on "Cytokine Signaling" (host: Prof. Heinrich Peter, RWTH-Aachen), October 3-5, 2002, Aachen.

12. "Erythropoietin receptor signaling", Université de Liège, Center for Cellular and Molecular Therapy (host: Prof. Jacques Piette), November 18, 2003, Liège.

13. "Signaling by cytokine receptors", Genethon, CNRS UMR 8115 (host: Dr. Mauro Mezzina), February 27, 2004, Evry.

14. Seminar Report for: Ludwig Institute for Cancer Research Scientific Advisory Board (host: Prof. Lloyd Old), July 7, 2004, New York.

15. ELSO Conference Nice, Stem Cell Symposium, September 9, 2004, Nice.

16. Invited Plenary Speaker, Multinational Assoc. Supportive Care in Cancer, EORTC, Erythropoietin treatment in cancer at the Anemia in Cancer Course for Oncologists, April 2005, Rome.

17. "Cytokine receptor signaling and Janus kinases at PamGene", October 5, 2005, Den Bosch.

18. Colloque of the French Society of Hematology on The JAK2 Mutation, Hôpital Avicenne Paris XIII University, November 18, 2005, Paris.

19. Seminar "JAK2 V617F and mutations in thrombopoietin receptor in myeloproliferative diseases", Research and Development Unit in Cancer Biosciences, Astra Zeneca, February 20, 2006, Waltham, MA.

20. "Erythropoietin receptor: Structure and function", Belgian Society of Radiotherapy (Board) Amgen Symposium on Erythropoietin, April 24, 2006, Liège.

21. "Epo effects in cancer treatment", Belgian and German Societies of Oncology Amgen Meeting, May 10, 2006, Zaventem.

22. "JAK2 V617F and cancer", Szent Istvan Univ. & Hungarian Acad. Sci. Applied Animal Genetics and Biotechnology, August 11, 2006, Gödöllö.

23. "Signaling by JAK2 V617F: a tale of kinases, receptors and friends of those", Molecular Haemopoiesis 9 Symposium, Kennedy Lecture Theatre, Institute of Child Health, 30 Guildfor Street, London WC1N 1EH, (Organizer, Prof. Anthony R. Green, University of Cambridge, UK), October 20, 2006, London.

24. "Traffic of thrombopoietin receptor in myeloproliferative diseases", Meeting of the ReceptEUR Marie Curie Research Training Network, November 21, 2006, Brussels.

25. "Signaling by JAK2 V617F and Mpl mutants in myeloproliferative diseases", Invited seminar at the Istituto Toscano Tumori (ITT), University of Florence, March 14, 2007, Florence.

26. "Signaling by JAK2 V617F and thrombopoietin receptor mutants in myeloproliferative diseases", 5th International Aachen Symposium on Cytokine Signaling, Universitätklinikum, March 29-31, 2007, Aachen.

27. "Signaling defects in human myeloproliferative diseases", Carl C. Icahn Center for Gene Therapy and Molecular Medicine and Division of Hematology, Oncology, Mount Sinai School, May 4, 2007, New York.

28. "Effects of JAK2 and JAK2 V617F on cytokine receptor forward routing", Molecular hematopoiesis workshop of the 12th Congress of the European Hematology Association (EHA), June 3-5, 2007, Vienna.

29. "JAK-STAT mutations in cancer: Lessons from hematology", invited seminar at the 17th World Congress of the International Association Surgeons, Gastroenterologists and Oncologists, September 6, 2007, Bucharest.

30. Symposium "Myeloproliferative and myelodysplastic syndromes", Invited lecture JAK2 inhibitors in the treatment of myeloproliferative diseases, September 20-22, 2007, Bergamo.

31. "Molecular basis, clinical implications and therapeutic perspectives of myeloproliferative neoplasms - JAK2 V617F, history of discovery of a mutation", Université catholique de Louvain, September 25, 2007, Brussels.

32. "Signaling by JAK2 V617F and thrombopoietin receptor mutants in human myeloproliferative diseases", invited seminar at the Section "Signaling pathways", The UK National Cancer Research Institute Conference (host: Prof. X. Lu), September 30 - October 3, 2007, Birmingham.

33. New Horizons in Hematology Conference: "JAK2 mutations in myeloproliferative diseases", 23rd General Meeting of the Belgian Hematological Society, January 25-26, 2008, Oostende.

34. "Aberrant JAK-STAT signaling in myeloproliferative neoplasms", European School of Haematology - Myeloproliferative Disorders, September 20, 2008, Athens.

35. "Molecular basis of human myeloproliferative neoplasms", Université de Liège, GIGA-Research Center (host: Prof. André Gothot), September 30, 2008, Liège.

36. "Perspectives for therapy in human myeloproliferative neoplasms", New Horizons in Hematology Conference, March 6-7, 2009, Paris.

37. "The JAK-STAT pathway", MiniSymposium on Immuno-Hematology organized by the Ecole Doctorale interuniversitaire d'immunologie FNRS and the Université catholique de Louvain, May 15, 2009, Brussels.

38. "Course of molecular medicine", Carol Davilla University of Medicine and Pharmacy, May 20-May 28, 2009, Bucharest.

39. "What does the future hold? Clinical implications of JAK2 and other molecular developments", Invited lecturer, Shire Satellite Symposia, 14th Congress of the European Society of Hematology (ESH), June 4, 2009, Berlin, Germany.

40. "Dissociating sequences required for constitutive versus ligand induced activation of JAK2 V617F", Invited speaker - Molecular Haemopoiesis Workshop, 14th Congress of the European Society of Hematology (ESH), June 5, 2009, Berlin.

41. Presentation to the Scientific Committee of the Ludwig Institute for Cancer Research Ltd (for promotion to the rank of Member), June 16, 2009, New York.

42. "Pathologic signaling via the Thrombopoietin Receptor", Cancéropôle Ile-de-France, June 26-27, 2009, Chantilly.

43. "JAK2 and TpoR mutations in human myeloproliferative neoplasms and perspectives for treatment", Symposium Biology, treatment and response monitoring of myeloproliferative neoplasms (MPNs), organized by Shire Pharmaceuticals, Brystol-Myers-Squibb and the Netherlands Hematology Society, June 30, 2009, Rotterdam.

44. "Signaling by JAK2 V617F and thrombopoietin receptor mutants in human myeloproliferative neoplasms: Identification of novel targets for small molecule inhibition", IRIBHM ULB (host: Prof. Jacques Dumont) September 24, 2009, Brussels.

45. "EPO-Receptors and survival", Société Luxembourgeoise d'Oncologie, September 30, 2009, Luxembourg.

46. "Growth factor utilization in cancer - Récepteurs cytokiniques de type I", Course organized by the EFEC (Ecole de Formation Européenne en Cancérologie), Institut Curie, October 8, 2009, Paris.

47. "Molecular drug targets in myeloproliferative disorders", 5th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes, November 5-7, 2009, New York.

48. "Molecular bases on hematopoiesis and molecular bases of myeloproliferative neoplasms", Master Class, University of Ghent Hospital, April 23, 2010, Ghent.

49. "Molecular bases of myeloid neoplasms", Novartis Institute for BioMedical Research, July 16, 2010, Basel.

50. "miR-28/LPP: molecular marker of human myeloproliferative neoplasms along JAK2 V617F and TpoR W515 mutations", Workshop on Perspectives of molecular medicine, Conference organized by the National Agency for Scientific Research, Stefan S. Nicolau Institute of Virology, Romanian Academy, September 23, 2010, Bucharest.

51. "New targets for therapy in myeloproliferative neoplasms: A pseudokinase domain helix C pocket in JAK2 V617F and pathologic mechanisms of thrombopoietin receptor down-modulation", European School of Hematology Congress on Myeloproliferative Disorders, September 30-October 2, 2010, Albufeira.

52. "From mutations to pathways: The impact on cell signalling", 6th Annual New Horizons in Hematology Conference, March 4-5, 2011, Zurich.

53. European Hematology Association Congress (16th EHA), Educational Session, Myeloproliferative disorders – Biology, June 9-12, 2011, London.

54. "Molecular bases of human myeloid neoplasms", Experimental Therapeutic Center and A*Agency, July 25, 2011, Singapore.

55. "From mutations to pathways: The impact on cell signaling defects in myeloproliferative neoplasms", Rencontres régionales 2011, Région Paris - Master Class Thrombocythémie essentielle, September 20, 2011, Paris.

56. "Signalling by JAK2V617F and cytokine receptors in human myeloid cancers", Ludwig Institute Cancer Biology Meeting, Eynsham Hall, September 28- October 2, 2011, Oxford.

57. "Targeting JAK2 V617F and the signaling pathways synergizing with it", 6th International Congress On Myeloproliferative Diseases And Myelodysplastic Syndromes, November 3-4, 2011, Brookline, NY.

58. "A new era for small molecule screening: from new targets, such as JAK2 V617F, to complex cellular screens", Myeloproliferative Neoplasms Masterclass organized by Hôpital St Louis Paris and Shire France, March 9-10, 2012, Paris.

59. "Mutations in MPN: Which one matters?", European Focus on Myeloproliferative Neoplasms and Myelodysplastic Disorders, May 3-5, 2012, Lisbon.

60. "Orientation-dependent signaling by cytokine receptors and JAK2 V617F in human myeloproliferative neoplasms", Cancer Stem Cell Meeting, Stanford University and Ludwig Center at Stanford, May 22-24, 2012, Stanford University, Palo Alto, CA.

61. "Actors of blood regeneration: erythropoietin, thrombopoietin and their receptors", ISAM (International Society of Adaptive Medicine) Congress, June 6-9, 2012, Bucharest.

62. "Mutated kinases and cytokine receptors in cancer and myeloproliferative diseases", Annual Mini-symposium: Signal transduction and cell cycle in proliferation and cancer, Doctoral School in Experimental Cancerology, Free University of Brussels (Université libre de Bruxelles), Erasme Hospital, September 13, 2012, Brussels.

63. "Beyond JAK2 V617F-pathogenesis and treatment targets in MPNs", New Horizons in Hematology, September 28, 2012, Stockholm.

64. "Pathologic thrombopoietin receptor signaling drives JAK2 V617F-associated MPNs", ESH International Conference on Myeloproliferative Neoplasms October 4-6, 2012, Vienna.

65. "Molecular bases of human myeloproliferative syndromes", Belgian Royal Academy of Medical Sciences, November 24, 2012, Brussels.

66. "Small molecule inhibitors in MPNs: are we aiming for the right targets?", Educational session at ASH (American Society of Hematology 2012), December 6-11, Atlanta, GA.

67. "Positive and negative signaling downstream cytokine receptors and JAK2 V617F in MPNs", Invited speaker at the 7th Post-ASH CMPL+MPN Workshop, December 11 and 12, 2012, Atlanta, GA.

68. “Inhibiting JAK1/2 in hematopoietic progenitors and stem cells: Can we prevent progression?”, MPN GOLS meeting (Myeloproliferative Neoplasms Global Opinion Leaders Summit), February 22-24, 2012, Helsinki.

69. “Structure-function studies on JAK2 and TpoR mutants and the bigger picture of selection pressures in MPNs", 3rd Annual Florence Meeting on Myeloproliferative Neoplasms & the Annual IWG-MRT Workshop, March 16-17, 2013, Florence.

70. “Role of JAK2 pseudokinase domain helix C in constitutive activation induced by the V617F mutation and on kinase domain dimerization”, oral presentation at the Exploring kinomes: pseudokinases and beyond meeting of the UK Biochemical Society, March 24-26, 2013, Cambridge.

71. “Intracellular signaling networks in chronic myeloid malignancies”, the European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes, April 5-7, 2013, Madrid.

72. “The medicine of the future: a dialogue with the human genome with major clinical perspectives”, Conference on personalized medicine, September 3, 2013, Bucharest.

73. “Future directions in MPN therapies”, European Hematology Association EHA 18 Satellite Symposium “Next steps for targeted therapy in MPN", organized by Novartis Oncology, June 13, 2013, Stockholm.

74. "Identifying genetic markers: implications for MPN patients today and tomorrow”, 8th Conference on New Horizons in Hematology (NHH8), September 21, 2013, Paris.

75. "Breaking pathologic signaling in myeloproliferative neoplasms”, The Ludwig Cancer Center retreat, Eynsham Hall, September 22-25, 2013, Oxford.

76. “Identification of novel transforming mechanisms and target pathways in JAK2-mutated MPN”, Advances in Myeloproliferative Neoplasms: Update 2013 Workshop, October 31, November 1, 2013, Vienna.

77. “Pathologic signaling by JAK2 V617F and TpoR mutants in myeloproliferative neoplasms”, Keynote lecture, Workshop “Differentiation, Stress and Death”, 17th Joint Meeting, Signal Transduction Society (STS), November 4-6, 2013, Weimar.

78. “Breaking Pathologic Signaling in Myeloproliferative Neoplasms”, Pierre Stryckmans Lecture awarded by the Belgian Society of Hematology, January 31, 2014, Ghent.

79. “Signaling in myeloproliferative neoplasms and therapies: Future”, ITMO (Instituts thématiques multi-organismes) Workshop on Myeloid Neoplasms, ITMO, February 16, 2014, Paris.

80. "Cytokine signaling in MPNs and MDS", European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes 2014, May 2-4, Prague.

81. "Pathologic signaling in myeloproliferative neoplasms", Institute seminar at the Center for Molecular Medicine (CEMM) of the Austrian Academy of Sciences (host R. Kralovics), May 7, 2014, Vienna.

82. "Will the CALR mutation be the new JAK2?", 9th New Horizons in Hematology Conference, Worldwide Medical Conference via MultiPlex and WebCast (host Dr. Sarah Jarvis), September 26, 2014, Paris.

83. "The New Long Acting G-CSF, Lonquex, a unique molecule", Teva Symposium Update on Neutropenia Management in Cancer Patients, September 29, 2014, Madrid.

84. "Mechanisms of JAK-STAT activation in myeloproliferative neoplasms", France InterGroupe Syndromes Myéloprolifératifs (FIM), Université Pierre et Marie Curie, October 3, 2014, Paris.

85. "MPN molecular pathways", European Leukemia Net (ELN) Frontiers Meeting 2014, October 16-18, 2014, Berlin.

86. "Structural basis of constitutive activation of JAK2 V617F and of cytokine receptor mutants in MPNs", International Conference on Myeloproliferative Neoplasms, October 23-25, 2014, Estoril.

87. "Thrombopoietin activates STAT2 inducing Type I interferon effects and gene expression: implications for in vivo Tpo treatment and for myeloproliferative neoplasms", (presentation with Isabelle Plo), American Society of Hematology Congress, December 9, 2014, San Francisco.

88. "Targeting JAK1/JAK2 in hematopoietic progenitors and hematopoietic stem cells", MPN GOLS 2015, February 27-28, 2015, Berlin.

89. "European focus on myeloproliferative neoplasms and myelodysplastic syndromes, current understanding of a genetic/epigenetic basis of classic MPNs", April 24-26, 2015, Zagreb.

90. "Genetic and biological markers in MPNs: How have they influenced clinical practice?", New Horizons in Hematology 10th Edition, March 6, 2015, Paris.

91. "Signaling alterations in MPNs", European Hematology Association (EHA), 20th Congress, Educational session, June 2015, Vienna.

92. "Pathologic JAK-STAT signaling in myeloproliferative neoplasms", 17th International Association for Comparative Research on Leukemia and Related Diseases (IACRLRD) symposium, September 21-23, 2015, Paris.

93. "Chaperones turned oncoproteins: calreticulin mutants pathologically activate TpoR and the JAK-STAT pathway in myeloid cancers", Weatherall Institute of Molecular Medicine (WIMM), March 15, 2016, Oxford.

94. "Structural and Molecular Bases of Pathologic Signaling by JAK2 and Tpo Receptor Mutants in Myeloproliferative Neoplasms : Perspectives for Therapy", Modern Trends in Human Leukemia and Cancer, XXI Wilsede Meeting, June 18-21, 2016, Wilsede.

95. "MPL Signaling in MPN", Euregionales comprehensive Cancer Center Aachen (ECCA), July 1-2, 2016, Eupen.

96. "Pathologic JAK2 activation in myeloproliferative neoplasms: from JAK2 V617F to calreticulin mutants", Scientific meeting of the FIM (France Intergroupe Syndrômes Myéloprolifératifs), November 4, 2016, Paris.

97. "Mutated chaperons as oncogenes : calreticulin mutants in blood cancer", Télévie Cancer Seminar 2017, December 8, 2016, Brussels.

98. "JAK2 signaling in hematological malignancies, new horizons", Novartis Satellite session, Meeting of the Belgian Hematology Society, February 11, 2017, Genval.

99. "Novel markers of blood cancers", Journée de Biologie clinique, Cliniques universitaires St Luc, May 13, 2017, Brussels.

100. "Voies de signalisation dans les néoplasies myéloprolifératives hors BCR-ABL", at the GFHC congress : "Néoplasies myéloprolifératives", May 17-19, 2017, Aix-en-Provence.
101. "JAK-STAT pathway in myeloproliferative neoplasms: from JAK2 V617F to calreticulin mutants" at the "JAK-STAT Signaling Symposium: new targets and therapeutics for multiple diseases" of the 37th SEF National Meeting with guest Society: the British Pharamcological Society, June 21, 2017, Barcelona.

102. "Current understanding on the cause and progression of myeloproliferative neoplasms and possible treatment targets" at San Francicso Myeloproliferative Conference organized by the MPN Foundation

(coordinator Prof. Ayalew Tefferi, Mayo Clinic), UCSF Mission Bay Campus, Genentech Hall, Beyers Auditorium, September 23, 2017 (live by WebEx).

103. " Driver mutations in myeloproliferative neoplasms and secondary myeloid leukemia: from JAK2 V617F to a mutated chaperone" Branch seminar and the Oxford Branch of the Ludwig Institute for Cancer Research and Nuffield Department of Medicine (organized by Prof. Xin Lu, Branch Director), University of Oxford, January 11, 2018, Oxford.

104. "Driving Myeloproliferative Neoplasms: STAT5 Activation from Mutants of JAK2 to Mutants of Calreticulin Activating TPO Receptor", at the "Final meeting of the Ludwig Boltzmann Institute for Cancer Research : From Receptors and Kinases to Transcriptional Regulators: Cancer Genome Landscapes and their Therapeutic Targets", May 6-9, 2018, Seggau.

105. "TPO receptor signaling & mutant CARL receptor", at the "8th International conference on myeloproliferative neoplasms, European School of Haematology (ESH)", May 15-17, 2018, Saggart.

106. " Driving Myeloproliferative Neoplasms via JAK2 V617F, Activating TpoR Mutants and Frameshift Calreticulin Mutants that Activate TpoR", Keynote lecture, at the " Molecular aspects of hematological disorders", June 12-13, 2018, Congress Centre Engels, Rotterdam.

107. "Role of TET2, TP53 in secondary AML" at the "23rd Congress of EHA", Scientific Working Group, June 14-17, 2018, Stockholm.

108. "MPN CALR mutants promote cell-surface localization of TpoR which is obligatory for oncogenesis: Novel therapeutic avenues and rescue of congenital thrombocytopenia TpoR mutants" presented by Christian Pecquet at the "23rd Congress of EHA", Presidential Symposium, June 14-17, 2018, Stockholm. Conference paper: Pecquet, C. et al. (2018) MPN CALR mutants promote cell-surface localization of TpoR which is obligatory for oncogenesis: Novel therapeutic avenues and rescue of congenital thrombocytopenia TpoR mutants. EHA Learning Center 2018, 215926.

109. "JAK2 V617F dimerizes homodimeric cytokine receptors cytosolic domains by requiring pseudokinase domain residues that promote JAK2 dimerization and oncogenic activity" presented by Emilie Leroy at "ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition", Oral and Poster Abstracts, December 1-4, 2018, San Diego.

110. "Secreted mutant calreticulins as rogue cytokines trigger thrombopoietin receptor activation specifically in CALR mutated cells: perspectives for MPN therapy" presented as one of six ASH Plenary Abstracts by Thomas Balligand at "ASH 2018 – 60th American Society of Hematology Annual Meeting and Exposition", Plenary Scientific Session, December 1-4, 2018, San Diego. Published conference paper: Pecquet, C. et al. (2018) Secreted mutant calreticulins as rogue cytokines trigger thrombopoietin receptor activation specifically in CALR mutated cells: Perspectives for MPN therapy. Blood 2018 132, 4.

111. "Myeloproliferative neoplasms: from drivers activating JAK2 to the STAT5-p53 connection in progression" at the "Erasmus Hematology Lectures 2018-2019", February 18, 2019, Rotterdam.

112. "Mutant calreticulins: rogue chaperones and cytokines in myeloproliferative neoplasms" at the "39^{e} Congrès de la Société Française d'Hématologie (SFH) ", March 27-29, 2019, Paris.

113. "Molecular evolution of progressive MPN" at "The XIV EBMWG International Workshop on Bone Marrow Pathology", April 11-14, 2019, Frankfurt.

114. ""Driver" mutations and "passenger" mutations contribute to the development of solid cancers and malignant hematological diseases " at "Stop Cancer Romania", May 10-12, 2019, Bucarest.

115. "Role of acquired phenotypic driver and epigenetic mutations in establishment and progression of myeloid blood cancers" at the "24th Congress of Young EHA research meeting (YERM)" European Hematology Association Congress, Key Note Lecture, June 13, 2019, Amsterdam.

116. "Novel targets in MPN: Status 2019" at "Precision Medicine in Hematology Working Conference", September 20-22, 2019, Medical University of Vienna, Vienna.

117. "CALR mutations in MPNs": Educational session "Mutational landscape in myeloproliferative neoplasms (MPN) and eosinophilia: Diagnostic and treatment", European Hematology Association (EHA) 25 Congress, Frankfurt, June 11-13, 2020, EHA 25 Virtual.

118. "New therapeutic targets in malignant disorders of the hematopoietic system". Honorary Scientist Lecture (equivalent DHC) at the National Institute of Pathology "Victor Babeş", Bucharest, 13th National Pathology Symposium, Bucarest, November 5-7, 2020.

119. "Is there a role for JAK1/JAK2 inhibitors in patients with severe COVID-19?", ESMO immuno-oncology, Virtal Congress, December 08, 2020. Virtual.

120. "Novel Targets in MPN - Update 2021", at "Closing Meeting SFB F47 Myeloproliferative Neoplasms - Pathogenesis and Development of New Therapeutic Strategies", January 27, 2021, Medical University of Vienna, Vienna – Virtual.

121. "JAK2 V617F and acquired JAK2 activating mutations from CHIP to clonal MPN diseases", Invited Speaker British Society of Hematology 2021, Myeloproliferative Neoplasms session, April 25-28, 2021, Virtual.

122. "Functional Consequences of Mutations in Myeloproliferative Neoplasms", Invited Plenary Lecture, European Hematology Association (EHA) 2021 Congress, June 13, 2021, Virtual.

123. "The JAK2 in ALL/PROTAC story", XVI Post ASH (American Society of Hematology) CML/MPN Workshop, December 15, 2021, virtual and Atlanta, GA, USA.